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ABSTRACT 
Title of the abstract: Prevalence and risk factors for osteoporosis in elderly men in a 
rural area of South India: a cross sectional study  
Department: Department of Community Health; CMC Vellore  
Name of the candidate: Dr. Reshma Raju 
Degree and Subject: MD Community Medicine  
Name of the guide: Dr. Vinod Joseph Abraham; Dept. of Community Health; CMC 
Vellore  
Name of the co-guide: Dr Thomas V Paul: Dept of Endocrinology ; CMC Vellore  
Objective: To determine the prevalence and risk factors of osteoporosis among 
ambulatory elderly men in the age group of 65 to 80 years in Kaniyambadi block 
Methodology: It was a cross sectional study design. Ambulatory elderly men (n=180) in 
the age group of 65-80 years were selected by simple random sampling from 
Kaniyambadi block. Sociodemographic details, physical activity, 10 year fracture risk 
assessment, 24 hour dietary calcium intake, biochemical parameters like calcium, 
albumin, creatinine and phosphate and Bone Mineral Density were assessed in all the 
patients.  
Results: The prevalence of osteoporosis and osteopenia at any one site in the community 
was 34.4% (95%CI: 27.31% to 41.48%) and 48.9 % (95%CI: 41.45% to 56.35%) 
respectively. On multiple logistic regression it was found that BMI (OR:8.3;95% CI: 
3.354-20.98 ; p value <0.001), serum albumin (OR: 2.56 ; 95%CI: 1.253-5.267               
;p value:0.010) and education (OR: a 2.43 ;95% CI: 1.050-5.628; p value: 0.038) of the 
subject had a significant association with osteoporosis.               
Conclusion: One out of three elderly men is osteoporotic in Kaniyambadi block. Low 
BMI, low serum albumin and lack of education are significantly associated with 
osteoporosis. 
Key Words: Osteoporosis, elderly men, serum calcium, serum albumin, physical activity 
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1. INTRODUCTION AND JUSTIFICATION  
 
India, the second most densely inhabited country in the world, also has a rising 
geriatric population. Statistics show that there are 76.6 million people at or above 60 
years of age which accounts for about 7.7% of the total population. Falls constitute a 
major problem in the elderly and hence are rightly termed as ‘Geriatric Giants’. 
Recurrent falls is a vital marker of poor physical and cognitive status as they 
constitute significant cause of morbidity and mortality in the elderly.  Falls occur as 
an outcome of a complex interaction between predisposing and precipitating factors in 
an individual’s environment .Most of these predisposing and precipitating factors are 
modifiable and if identified early and addressed adequately can reduce the fall rates 
significantly (1). The total number of hip fractures worldwide in 1990 was 1.26 
million (2,3). It is estimated that, given there is no change in age specific and sex 
specific incidence of hip fractures, there will be 2.6 million and 4.5 million hip 
fractures in 2025 and 2050 respectively (2,3). 
The economic impact of osteoporosis is huge. According to International 
Osteoporosis Foundation data, in Europe, apart from lung cancer, the disability owing 
to osteoporosis is much greater than that contributed by cancers. The cost burden of 
this disease worldwide is expected to increase to USD (United States Dollar) 131.5 
billion by the year 2050 (4). 
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Studies have shown that morbidity and mortality  are much higher in 
osteoporotic men when compared with women (5). In developing countries like India, 
where men may be the only earning member in the family, such a health condition 
may push poor families into a vicious cycle of poverty debt and ill health (5). 
There is paucity of data on male osteoporosis, an important factor which 
contributes to fractures in elderly, and thus warrants further research. In order to 
effectively target osteoporosis and implement programmes, policy makers require 
precise projections of the burden of the disease (6).  
This study is aimed to assess the prevalence of osteoporosis in elderly men in 
South India so that preventive strategies can be initiated early and hence decrease the 
disease burden in the community.   
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2. OBJECTIVES 
 
 
• To determine the prevalence of osteoporosis among ambulatory 
elderly men in the age group of 65 to 80 years in Kaniyambadi block 
 
• To determine the risk factors for osteoporosis in the same population 
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3.  REVIEW OF LITERATURE 
 
Osteoporosis according to WHO (World Health Organization), is a “disease 
characterized by low bone mass and micro architectural deterioration of bone tissue, 
leading to enhanced bone fragility and a consequent increase in fracture risk” (1). The 
National Institute of health (NIH) Consensus Development Panel on Osteoporosis 
defines osteoporosis as “a skeletal disorder characterized by compromised bone 
strength predisposing a person to an increased risk of fracture” (7). Most people 
regard osteoporosis as a disease of women. Osteoporosis is rightly called “the silent 
disease” as it advances devoid of symptoms until fracture occurs (8). The commonest 
places where fractures occur are vertebrae, hip and wrist. ‘Fragility fractures’ is the 
terminology used to describe fractures which result as a consequence of secondary 
osteoporosis (8). Osteoporotic fractures results in significant morbidity, disability and 
inferior quality of life in the elderly. The past 30 years have witnessed a two to three 
fold increase in hip fracture rates throughout Asia (9). Hip fractures also can lead to 
early death and cause a substantial fiscal burden on the family and society (10). 
Figure 3.1 represents the burden of diseases depicted in DALYs (Disability Adjusted 
Life Years) for Europe and the United States.  
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Figure 3.1  Disease burden represented as disability-adjusted life years (DALYs) for   
USA and European countries together [ 2002 data] (11)  
 
[Source: “WHO Scientific Group On The Assessment Of Osteoporosis At Primary Health Care Level; 
Summary Meeting Report ;Brussels, Belgium, 5-7 May 2004”] 
Lately osteoporosis in men has been recognized as a significant public health 
problem as the life expectancy is increasing and the number of elderly men will 
continue to rise (5,8).  
3.1 Prevalence of osteoporosis 
International osteoporosis Foundation states that “worlds annual number of hip 
fracture will rise from 1.26 million cases in the year 1990 to 2.6 million by the year 
2025 and to 4.5 million by 2050” (12). Reliable epidemiological data are lacking from 
India. Data suggests that men are probably affected more than women. This also 
could be due to the fact that men are likely to seek medical attention than women in 
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India. In a study done in the Christian Medical College, Vellore in subjects above 50 
years of age between 2009 and 2011, osteoporosis of the spine and hip were 
diagnosed in 42.7% and 11.4% subjects by Hologic DXA-4500 series database (13). 
However in the same study, on using the ICMR (Indian Council of Medical Research) 
database, the prevalence was markedly low, was reported to be  27.7% and 8.3% in 
the spine and hip respectively (13). In men aged above 60 years, the prevalence of 
osteoporosis was 45% (5). Table 3.1 and Table 3.2 represent the burden of 
osteoporotic fracture worldwide. 
 
 
 
 
 
 
Table 3.1 Prevalence of osteoporosis among elderly men and women (4,14–16). 
Population Prevalence of fracture  due to osteoporosis Worldwide 
Women 
> 50 years 33% 
>  60 years 50% 
Men 
 
> 50 years 20% 
       > 60 years 33% 
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Table 3.2  Site specific and total number of osteoporotic fractures , in men and women more 
than or equal to 50 years , in various  WHO regions (11) 
 
  Expected number of fractures by site(thousands) All osteoporotic 
fractures  
WHO region Hip Spine Proximal humerus Forearm Number Percent 
Africa 8 12 6 16 75 0.8 
Americas 311 214 111 248 1406 15.7 
South East 
Asia 221 253 121 306 1662 17.4 
Europe 620 490 250 574 3119 34.8 
Eastern 
Mediterranean 35 43 21 52 261 2.9 
Western 
pacific 432 405 197 464 2536 28.6 
Total 1672 1416 706 1660 8959 100 
[Source: “WHO Scientific Group On The Assessment Of Osteoporosis At Primary Health 
Care Level; Summary Meeting Report ;Brussels, Belgium, 5-7 May 2004”] 
 
Figure 3.2 Hip fracture incidence of Rohtak (17)  
[Source: “ International Osteoporosis Federation. The Asia Pacific Regional audit: Epidemology, costs and 
burden of osteoporosis in 2013”.] 
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Figure 3.2 represents the age and sex specific  incidence of hip fracture in the 
year 2009 in Rohtak district, North India .The incidence of hip fracture starts rising 
after 65 years of age in both men and women.  
3.2.  Difference between osteoporosis in men and post menopausal osteoporosis 
The lifetime fracture risk for men is between 13 to 25 percent unlike women in 
whom it much higher reaching to 50 percent. Vertebral fracture prevalence increases 
both in men and women however the gradient is much steeper in women as is 
depicted in the Figure 3.3 (18). However fracture related morbidity and mortality is 
significantly elevated in males than in females (19).  
Figure 3.3 “Age-specific and sex-specific  radiographic vertebral, hip, 
and distal forearm fracture incidence” (20) 
 
[ Source: European Prospective Osteoporosis Study  (21) and General Practice Research Database (22)] 
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3.3 Osteoporosis and an ageing population  
The current population in India is 1.2 billion (17). Ten percent of this 
population is aged more than 50 years old (17). The current average life expectancy of 
an Indian is 67 years. The projected population for the year 2050 will be 1.88 billion, 
of which 33% will be more than 50 years of age. The life expectancy of and average 
Indian in the year 2050 will be 77 years (17). These statistics point towards an ageing 
population subsequently resulting in a rise in the number of elderly falls (23). Figure 
3.4 and Figure 3.5 represent the life expectancy and the population projection of India 
respectively. It is estimated that worlds  number of hip fracture per year will go up 
from “1.26 million cases in the year 1990 to 2.6 million by the year 2025 and to 4.5 
million by the year 2050” (17).Majority of these fractures can be attributed to 
osteoporosis (17).  
Figure 3.4 Life expectancy in India  (17)  
 
[Source: “International Osteoporosis Federation. The Asia Pacific Regional audit: Epidemology, costs and 
burden of osteoporosis in 2013”]  
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Figure 3.5 Population projection for India until 2050 (17)   
    
   
[Source: “International Osteoporosis Federation. The Asia Pacific Regional audit: Epidemology, costs 
and burden of osteoporosis in 2013”] 
 
3.3.1 Medical Impact of osteoporosis 
The most important clinical sequel of osteoporosis is a fractureand its 
associated consequences. The common sites of fractures due to osteoporosis are spine, 
proximal femur and distal forearm. The outcome of fractures can either be full 
improvement or pain, disability and even fatality. As a result of the fracture patients 
may experience psychological symptoms like low self esteem and depression due to 
the tenderness, disability and lifestyle modification. The high morbidity and 
subsequent dependency as a result of the fracture can damage interpersonal 
relationships and social interactions of the patient and their care givers (24).  
There is a 2.5 times increased risk for future fractures in people with hip 
fracture and they can have 10-20% excess mortality within the first year. Around 20% 
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of these patients require prolonged stay in a nursing home. Pre-fracture level of 
independence is regained only by 40% of these patient (24–26).Wrist fractures may 
be less disabling but can result in restrictions of activities of daily living. Mortality is 
also high with vertebral fractures and it also causes people to have long term pain and 
disability (24). 
3.3.2 Economic toll 
A report from the Surgeon General (US) 2004 estimates that there are 432,000  
admissions to the hospitals, almost 2.5 million consults with the medical officers and 
about 180,000 admissions in various nursing homes per year in the US as a 
consequence of osteoporotic fractures (25). The cost to the health care delivery 
system is also high which is estimated to be at least $17 billion in the year 2005 (6). 
In the US the number and related costs of fractured hip could become two or three 
times by 2040 due to the aging population. In India the cost of treatment of fracture 
varies depending on the place and type of health facility as in whether it is private 
clinic or government hospital. The cost of hip surgery in a private hospital is about Rs 
1,50,000 to 2,50,000/- (2,360-3,860 USD) and the duration of stay will be 
approximately 5-6 days. In a government hospital the cost will be only 50,000/- but 
the duration of stay will be 15 days (27).  
3.4 Risk factors associated with falls in the elderly 
Among the several causes of falls in the elderly, accidental or environment 
related is the most common, accounting for 30-50% of the cases. Next in the list is 
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gait problems and weakness contributing for 10-25% cases. Gait abnormalities can be 
either due to simple age related changes or specific dysfunctions involving nervous, 
muscular or skeletal systems. Another major factor which contributes to fall among 
elderly is dizziness which is very common in this age group. Several factors such as 
cardiovascular dysfunction, orthostatic hypotension, drug side effects may be 
responsible for this. About 2-10% of the falls can be attributed to syncopal attacks or 
sudden loss of consciousness. Other specific causes include  neurovascular diseases, 
poor cognition, visual disturbances, adverse effects of drugs, anemia, alcoholism, 
severe osteoporosis with spontaneous fracture (28). [See Table 3.3]  
Table 3.3 Risk factors for fall  
Medical factors Neuromuscular factors Environmental factors 
• Elderly age group 
• Cardiac arrhythmias  
• Pscychiatric 
ailments  
• Malnutrition  
• Reduced mental 
acuity 
• Dehydration  
• Orhtostatic 
hypotension  
• Vitamin D 
deficiency  
• Sedative drugs  
• Muscle weakness 
• Lack of 
proprioception  
• Poor balance  
• Kyphoscoliosis  
• No assistive devices 
in the bathroom for 
the elderly 
• Slippery floor 
• Poor lighting  
• obstacles in the path 
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3.5 Basic pathophysiology 
Peak bone mass is attained by the age of 18-25 years and it is dependent on 
various factors such as genetics, diet, endocrine disorders, exercise and health during 
growth. Because of bone remodeling the older bone is continuously replaced by 
newer bone. When this equilibrium is lost as in menopause and advancing age, where 
by bone removal is more than replacement it results in bone loss (24). Figure 3.4 and 
Figure 3.5 represents the micrograph of a normal and osteoporotic bone respectively 
(29).  
Figure 3.6 Micrograph of normal bone (24) 
 
 
 
 
 
 
 
 
 
[Source: “Clinicians guide to prevention and treatment of osteoporosis. 
National Osteoporosis Foundation”] 
 
Figure 3.7  Micrograph of osteoporotic bone (24) 
 
[Source: “Clinicians guide to prevention and treatment of osteoporosis. 
National Osteoporosis Foundation”] 
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As a result of bone loss there will be disordered skeletal architecture and changes in 
the cancellous bone which can lead to fractures. There is loss of trabecular plates of 
bone resulting in structurally frail skeleton which increases bone fragility and fracture 
risks. 
 Figure 3.8 Pathogenesis of osteoporosis related fractures (30) 
[Source: “Clinicians guide to prevention and treatment of osteoporosis. 
National Osteoporosis Foundation”] 
 
Figure 3.8 represents the various general and specific causes of osteoporotic  
fractures. Ageing, hypogonadism, menopause, other medical risk factors and 
increased bone turnover lead to increased bone loss. This along with inadequate peak 
bone mass leads to impaired bone quality and low bone density. In addition to this 
various factors such as increased propensity to fall and fall mechanics will result in 
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skeletal bone fragility and increased bone loading which finally culminate in fracture 
bone (30).  
3.6 Bone loss linked with aging in men    
When compared to females, males have larger bones, have greater bone 
strength and reduced risk of fractures. From middle age, the bone loss in men starts 
progressing. Men in contrast to women have a lower resorption of the endocortex  and 
a greater expansion of periostium. The periosteal apposition may work against the 
cortical thinning produced by endocortical resorption. This result in lower total bone 
loss compared to women which ultimately leads to an absolute increase in the size of 
the bone. Reduced bone formation leads to trabecular thinning resulting in bone loss 
in elderly men (31). The role of estrogen, androgen and Sex Hormone Binding 
Globulin (SHBG), in the pathogenesis of osteoporosis in men, needs to be clarified. 
The most dreaded complication of  bone loss is hip fracture which is more in men in 
comparison to women (5).   
3.7 Causes and risk factors of osteoporosis in men 
Several factors contribute to osteoporosis and subsequent fractures in men. It 
can be classified as “modifiable” and “non-modifiable” risk factors. Non-modifiable 
risk factors include gender, age, ethnicity, family history, body frame. Some of the 
modifiable risk factors include  lack of physical activity, low dietary calcium intake, 
low vitamin D levels due to lack of sunlight exposure, eating disorders, excessive 
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alcohol intake, smoking. Bariatric surgeries and post-gastrectomy status can also 
cause osteoporosis due to the reduced surface area available for the absorption of 
nutrients. Another important factor is use of medications such as steroid, 
anticonvulsant and chemotherapeutics .Endocrine disorders such as hyperthyroidism, 
hyperparathyroidism, and hypogonadism are some of the other identified risk factors 
(12,17–19,21). 
Some chronic diseases such as coeliac disease, inflammatory bowel disease, 
rheumatoid arthritis, chronic liver or kidney disease also contribute to this condition 
(32–34).Studies done in COPD (Chronic Obstructive Pulmonary Disease) patients to 
determine the prevalence of osteoporosis among them revealed a  higher prevalence 
of osteoporosis. Glucocorticoid use alone could not explain the increased prevalence 
of osteoporosis in them (35). 
Reduced physical activity is a key risk factor for osteoporosis. Studies show 
that weight bearing physical activity during formative years contributes to increased 
peak bone mass. This will give the mechanical stimuli or ‘loading’ which is essential 
for the preservation of bone health. It also reduces the rate of bone loss later in life 
(36).When the physical activity is increased, the risk of fractures in the future is less 
(37).  
Table 3.4 describes the causes of osteoporosis in men classified into primary 
and secondary causes. The causes of primary osteoporosis are age related and 
idiopathic. Secondary osteoporosis occurs as result of certain medical conditions or 
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drugs which interfere with bone remodeling and lead to increased bone loss. Factors 
such as renal failure, cushing’s disease, liver impairment , alcoholism, steroid use, 
hypogonadism, drug induced, COPD are the main causes for secondary osteoporosis 
in men (31). 
Table 3.4 Primary  and secondary osteoporosis in men (24,31) 
Primary Osteoporosis 
•  Osteoporosis associated with 
ageing 
• Idiopathic  
Secondary Osteoporosis 
• Alcohol addiction 
• Glucocorticoid use 
 Exogenous 
 Endogenous 
• Hypogonadism 
 Idiopathic 
 Androgen deprivation therapy for 
prostate   cancer 
• Chronic obstructive pulmonary 
disease 
• Gastrointestinal diseases  
 Malabsorption syndromes 
 Celiac sprue 
 Primary biliary cirrhosis 
 Inflammatory bowel disease 
 Bariatric surgery 
 Postgastrectomy 
• Hypercalciuria 
• Hyperthyroidism 
• Hyperparathyroidism 
• Medication related 
 Anticonvulsants 
 Chemotherapeutics 
 anti coagulants (heparin) 
 aromatase inhibitors 
 gucocorticoids(≥5mg/d of 
prednisolone or equivalent for 3 
months) 
 Lithium 
• Thyroid hormone 
• Neuromuscular disorders 
• Post-transplant osteoporosis 
• Systemic illnesses 
 Mastocytosis 
 Thalassemia-induced osteoporosis 
 Monoclonal gammopathy 
 Other malignancies 
 Human immunodeficiency virus 
(HIV) infection 
 Rheumatoid arthritis 
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3.8 Evaluation of osteoporosis in men  
Assessment of BMD (Bone Mineral Density) is essential to establish the 
diagnosis of osteoporosis which is the gold standard (38). It is proven that the 
strongest risk factor for fracture is a low BMD. For people who are at risk, a clinical 
diagnosis can easily be made in case of a low trauma fracture.  
3.8.1 Indications for DEXA scan  (24) 
According to the National Osteoporosis Foundation (NOF), the decision to 
screen for osteoporosis depends on each person’s fracture risk profile and bone health 
estimation (24). Bone Mineral Density measurement is not recommended unless the 
result will affect his or her treatment decision. It is not advised in children, 
adolescents, young men or premenopausal women. Table 3.5 lists the indication for 
BMD testing according to NOF guidelines.  
Table 3.5.  Indications for BMD testing (24) 
• Adults above 50 years with a fracture 
• Adults with a medical condition like rheumatoid arthritis or on treatment 
with steroids and with reduced bone mass 
• Subjects requiring  treatment for osteoporosis  
• To monitor treatment effect of patients on treatment for osteoporosis  
• people currently  not on therapy in whom evidence of bone loss would 
initiate  treatment 
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3.8.2 Definition of osteoporosis based on BMD 
Screening for osteoporosis in men is recommended above 70 years of age (5). 
Bone mineral density measured by a DEXA (Dual Energy X ray absorptiometry) is 
the gold standard in diagnosis of osteoporosis. Areal BMD can be expressed both in 
absolute and relative terms. In absolute terms BMD can be expressed as grams of 
mineral per square centimeter scanned (g/cm2) (24). The Z-score represents the areal 
BMD compared to the BMD of a matched reference population, age, sex and 
ethinicity being matched. The T-score on the other hand represents the BMD 
compared to the BMD of a young adult in the reference population of the same sex 
(24). In order to calculate the T-score and Z-score, divide the difference between the 
patients BMD and the mean BMD of the reference population by the standard 
deviation of the reference population (24). 
Table 3.6  “WHO definition of Osteoporosis Based on BMD” (24) 
Classification  BMD T-score  
Normal  
 
“Within 1 SD of the mean level for a 
young-adult reference population”  
 
“T-score at -1.0 and 
above” 
 
Low Bone Mass 
(Osteopenia)  
 
“Between 1.0 and 2.5 SD below that 
of the mean level for a young-adult 
reference population” 
 
“T-score between -1.0 
and -2.5” 
 
Osteoporosis  
 
“2.5 SD or more below that of the 
mean level for a young-adult 
reference population” 
 
“T-score at or below -
2.5”  
 
Severe or 
Established 
Osteoporosis  
 
“2.5 SD or more below that of the 
mean level for a young-adult 
reference population” 
 
“T-score at or below -
2.5 with one or more 
fractures” 
[Source: “Clinicians guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation”] 
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Definition of osteoporosis is based on the bone mineral density. According to 
the WHO criteria for the diagnosis of osteoporosis, it has been defined as a “BMD 
that lies 2.5 standard deviations or more below the average value for young healthy 
women (a T-score of <-2.5 SD)” (24). The diagnosis based on BMD, as “normal”, 
“osteopenia”, “osteoporosis” and “severe and established osteoporosis” is dependent  
on the WHO diagnostic classification shown in Table 3.6 (24). 
BMD of lumbar spine, hip, forearm, heel and fingers can be calculated to 
predict the site specific and the overall assessment of future fracture risk. However 
BMD assessment of the hip is the best predictor of potential hip fracture risk in the 
future.  In men above 50 years of age the diagnosis of osteoporosis is based on the 
WHO diagnostic T-score criteria applied to BMD measurement by central DEXA at 
the lumbar spine and femoral neck (24). According to the International Society for 
Clinical Densitometry (ISCD) in men less than 50 years, in the place of T-score, 
ethnic or race adjusted Z-scores should be considered. In this group of patients with 
Z-scores of -2.0 or lower is classified as either “low bone mineral density for 
chronological age” or “below the expected range for age” and those with Z-score of 
more than -2.0 being “within the expected range for age” (24). 
One of the main problem with the measurement of BMD is that it has high 
specificity but low sensitivity which signify that the fracture risk is more in the 
presence of low BMD but is not negligible in case of normal BMD. So a greater part 
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of the osteoporotic fractures occurs in patients with a DEXA scan. Hence experts do 
not advise the mass screening of BMD.  
3.8.3 DEXA Machine: 
Dual-energy X-ray absorptiometry (DEXA) scanning was designed for the 
diagnosis of osteoporosis. It was primarily used to clinically analyze the main sites 
such as the lumbar spine, femoral neck and forearm. The hasty acceptance of DEXA 
has led to the development of dissimilar, contending generations of the device. 
Improvements have been made through introduction of latest technologies in X-ray 
production and detection, modification of data acquirement protocols, and 
accomplishment of more complex image analysis algorithms. Thus the use of DEXA 
has allowed the study of the total skeleton, regional parts, and also the soft-tissue 
composition measurement. This technology has given the ability to easily measure 
with greater precision and low scanning time, the body fat mass, lean mass and bone 
mineral density(39).  
A  Hologic Dual energy X-Ray absorptiometry (DEXA) machine (Discovery 
A- QDR 4500) has a one pass single sweep scanning system for better quality and 
precision. It also eliminates beam overlap errors and image distortion encountered in 
rectilinear acquisition techniques resulting in a better image quality and data stability. 
It has a multi-element digital detector array along with true fan-beam acquisition 
geometry, enabling rapid, dual-energy bone density measurements. 
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3.8.4 Use of WHO Fracture Risk Algorithm (FRAX)  
FRAX is a tool which was designed to calculate the 10 year probability of a 
hip fracture and the 10 year probability of a major osteoporotic fracture which can be 
either a vertebral, hip, forearm or proximal humerus fracture using femoral neck 
BMD and various clinical risk factors. Quite a few risk factors were included in the 
WHO 10-year fracture risk model. Given below is the Table 3.7 containing those risk 
factors which are considered to predict the 10 year fracture risk (24). 
Table 3.7 Factors included in WHO fracture risk assessment model (24) 
Risk factors included in the WHO Fracture Risk Assessment Model 
• Current age  
• Gender  
• A prior osteoporotic fracture 
(including morphometric vertebral 
fracture)  
• Femoral neck BMD  
• Low body mass index (kg/m2)  
• Oral glucocorticoids ≥5 mg/d of 
prednisone for ≥3 mo (ever)  
 
• Rheumatoid arthritis  
• Secondary osteoporosis  
• Parental history of hip fracture  
• Current smoking  
• Alcohol intake (3 or more 
drinks/d)  
 
  Other laboratory tests mentioned in Table 3.8 may be required in order to find 
out the cause of the disease (31).  
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Table 3.8 Laboratory tests in the evaluation of male osteoporosis 
(31) 
Other investigations  
Serum calcium 
Serum phosphorus 
Serum  creatinine 
Alkaline phosphatase 
Liver function tests 
Complete blood count 
 Protein electrophoresis 
Serum 25-hydroxy-vitamin D 
Serum testosterone 
 Sex hormone binding globulin 
 Luteinizing hormone 
Additional second line tests 
Parathyroid hormone, thyroid function 
24-h urinary calcium and creatinine 
24-h urinary cortisol 
Biochemical indices of bone remodeling 
Immunological tests for sprue 
  
. 
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3.8.5 Other Bone densitometry Technologies 
There are several bone mass measurement technologies which are able to 
predict site specific and overall fracture risks. These newer technologies are capable 
of giving accurate and highly reproducible results if performed according to the 
acceptable standards. 
• Peripheral Dual-Energy X-ray Absorptiometry (pDXA): This measures the 
areal bone density of peripheral bones such as forearm, fingers and heels. It can 
also be used to measure the bone density of vertebrae. Though it can be used to 
predict the overall fracture risk in women there is not enough evidence regarding 
fracture prediction in men. It is not useful in monitoring BMD during or after 
treatment(24).  
• CT based absorptiometry: Quantitative computed tomography (QCT) measures 
volumetric trabecular and cortical bone density at the spine and hip. Peripheral 
QCT is used for the forearm or tibia. It can be used to predict fracture risks in 
women but there are no sufficient data to suggest its usefulness in fracture 
prediction in men. The radiation exposure associated with this modality is much 
higher than the DEXA (24).  
 
• Quantitative ultrasound densitometry (QUS): It measures the “speed of sound 
(SOS)” and or “broadband ultrasound attenuation (BUS)” at various bones. It can 
be used to predict fracture in post menopausal women and men above 65 years of 
25 
 
age. The fact that it is not associated with any radiation exposure is an added 
advantage (24). Calcaneal QUS still remains the commonest modality of diagnosis 
of osteoporosis in places where DEXA scan are not available (40). 
 
3.9 Recommendations for all patients  
Several strategies can be provided for all patients to reduce fracture risks. 
These include appropriate amount of calcium and vitamin D in the diet, regular 
involvement in  weight-bearing and muscle-strengthening physical activities, 
cessation of smoking and alcoholism, and treatment of other risk factors for fracture 
such as lack of vision, loss of balance, giddiness etc.  
• Dietary Calcium and Vitamin D: Human skeletal system contains almost 99% of 
the body’s calcium stores. When the dietary intake of calcium is low; there will be 
bone resorption from the skeleton to preserve the serum calcium at a constant level. 
Vitamin D plays a major role in the absorption of calcium. According to the NOF, 
an intake of 800 -1000 IU (International Unit) of vitamin D per day for adults older 
than 50 years of age is required. The expected level of serum 25 (OH) Vitamin D 
level is 30 ng/ml (75 nmol/L) or higher. Studies have shown that supplementation 
of calcium and vitamin D combinations can effectively diminish fracture risks. All 
individuals are recommended to have a minimum of 1200mg of dietary calcium 
including supplements. The main dietary sources of vitamin D include milk, 
cereals, egg yolk, salt water fish and liver. The present recommendation to reduce 
26 
 
sodium, increase potassium and fresh fruit and vegetables is improbable to be 
harmful for bone health (10). However vegetarian diet alone has not proved any 
beneficial effect. The presence of high contents of phytates, oxalates and fiber 
promotes calcium resorption and its secretion in the urine (41).  
• Physical activity: Regular physical activities reduce the risks of falls and fractures. 
Health benefit of regular exercise includes improvement in strength, posture and 
balance. It also improves the bone density. As the benefits of physical activity 
stops when the person stops exercising it is strongly recommended to persist in 
exercise at all ages. Weight bearing exercises are those in which both the bone and 
the muscles work against gravity while the feet and the legs bear the body’s 
weight. Some examples of weight bearing exercise include walking, jogging, 
dancing, climbing stairs and playing tennis (24). 
• Fall prevention: Strategies to prevent falls include regular checking and correcting 
of vision and hearing, evaluating any neurological problems. Alternate medicines 
can be prescribed for those drugs which may affect balance (24).  
• Avoidance of tobacco use and excessive alcohol intake. The use of tobacco is 
disadvantageous to the bone health. Hence elderly men should be encouraged to 
avoid smoking.  Excessive drinking defined as three or more units of alcohol per 
day is injurious to the bone. It also enhances the chance of falling (24). . 
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3.10 Treatment of osteoporosis in men  
General measures to prevent fractures needs to be adopted in every elderly man 
as is the case with women. These include good nutrition, adequate calcium intake, 
regular exercise, avoiding harmful lifestyle factors (e.g., smoking cessation). Due to 
high prevalence of vitamin d deficiency, its supplementation should be considered 
always in order to achieve adequate blood level (31).  
The underlying cause of osteoporosis should always be investigated and treated if 
possible.  
3.10.1 Subjects requiring treatment? 
Post menopausal women and elderly men above 50 years in any of the following 
situation should be offered medical management. 
• Any fracture in the hip or spine  
• femoral neck or spine T-score ≤ -2.5  after excluding  secondary causes  
• “T-score between -1.0 and -2.5 at the femoral neck or spine along with a 
10-year probability of a hip fracture ≥ 3% or a 10-year probability of a 
major osteoporosis-related fracture ≥ 20%” (24). 
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Assessment of the patients with suspected osteoporosis can be done by following the 
algorithm shown in Figure 3.9.  
Figure 3.9 Algorithm for assessment of osteoporosis (24) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A detailed history with focus on clinical risk factors for osteoporosis associated 
fracture 
Through physical examination to look for signs of osteoporosis or secondary 
causes. 
 
Life style and dietary modification for prevention of fracture 
 
Estimate patient’s 10-year probability of hip and any major osteoporosis-related 
fracture using the WHO algorithm. 
 
Treatment decisions based on clinical judgment  
 
Medical therapy based on the following criteria: 
• Fracture of vertebrae or hip 
• Hip  or spine T-score ≤ -2.5 
• Low bone mass and a US-adapted WHO 10-year probability of a hip 
fracture ≥ 3% or 10-year probability of any major osteoporosis-related 
fracture ≥ 20% 
• Individual  preferences  
 
 
Consider non-medical therapeutic interventions: 
• Revise risk factors which lead to falls 
• Use of walking aids and hip pad protectors 
• Weight-bearing exercises routinely  
 
• Frequent review  of patients  
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Medical therapy available for prevention and treatment of osteoporosis in 
women are bisphosphonates and calcitonin. Other drugs are estrogens (estrogen 
and/or hormone therapy), estrogen agonist/antagonist (raloxifene) and parathyroid 
hormone [PTH (1-34), teriparatide]. Examples of bisphosphantes include alendronate, 
alendronate plus D, ibandronate, risedronate, risedronate with 500 mg of calcium 
carbonate and zoledronic acid. everal randomized controlled trials were under taken in 
men to test various pharmacological agents useful for treatment in men. Most of these 
were short term trials with small sample size and hence lacks power to make 
conclusive evidence on the drug effects on fracture risks (31).  
Studies show that bisphosphonates, strontium ranelate, teriparatide and 
denosumab improve bone mineral densities in men with both primary and secondary 
osteoporosis. The beneficial effects of bisphosphonates and teriparatide on bone 
mineral density were independent of age and gonadal function. Study done comparing 
use of  bisphonates versus placebo  and incidence of new vertebral fractures showed a 
statistically significant difference between the two (31).The treating physician should 
weigh the potential risk versus benefit in treating with pharmacological agents in each 
case. 
3.10.2 Bisphosphonates 
Bisphonates are anti-resoptive agents. Osteoporosis as well as other metabolic 
bone diseases such as pagets disease and tumor associated bone diseases are 
effectively treated with this drug. The strong binding property of bisphosphonates 
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with the bone prevent osteoclast mediated bone resorption. This results in the anti-
resoptive property of bisphosphonates. Bisphonates are the treatment of choice for 
most men with osteoporosis (42).  
3.10.3 Alendronate 
Another drug approved in treating men with osteoporosis is Alendronate. It 
represents a vital and desirable medical advancement in the management of 
osteoporosis in men (43). Alendronate decreases the 3 year future risk of fractures 
(spine or hip), by 50% in those with earlier fractures and 48% in those without an 
earlier fracture. The preventive dose recommended is 5mg once daily or 35mg once 
weekly. The therapeutic dose is double the preventive dose or 70mg once weekly with 
Vitamin  D3 (2800IU or 5600IU) (24,42). The safety and tolerability of alendronate in 
men is similar to that observed for post menopausal women (43).The incremental 
benefit of Alendronate in increasing bone density and thus preventing fractures has 
been proven in earlier studies. It also prevents decline in height (44). A Swedish study 
concluded that treating men with osteoporosis was cost effective (45).  
3.10.4 Risedronate 
Risedronate is also used for management of osteoporosis in men. It increases 
the bone mass. Incidence of spine fracture reduces by 41-49 percent and other 
fractures by 36 percent after treatment with risedronate for over three year. Studies 
show that there is a marked reduction in the risk even with treatment for one year in 
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patients with previous vertebral fractures. Several dosage regimens are available 
which include “ 5 mg daily tablet; 35 mg weekly tablet; 35 mg weekly tablet along  
with six tablets of 500 mg calcium carbonate; 75 mg tablets on two consecutive days 
every month; and 150 mg monthly tablet” (24). A multinational randomized  double 
blinded placebo controlled two year study done to evaluate the efficacy and safety of 
35 mg weekly once dose of risedronate in men with osteoporosis, it was seen that 
there was a significant increase in the lumbar spine BMD from the baseline (4.5%; 
95% CI: 3.5%, 5.6%; p < 0.001) (46). However there was no drop in incident 
fractures with the use of risedronate as these arise rarely and this study was not 
powered to capture improvements in fracture end points (47). Hence more studies are 
needed to determine the anti-fracture efficacy of risedronate (47).  
3.10.5 Zoledronic acid 
Zoledronic acid is also an approved drug for treatment of osteoporosis in men. 
Incidences of spine fractures are reduced by 70 percent with considerable reduction of 
risk at the end of one year. It also reduces the incidence of hip fracture and non-
vertebral fractures by 41 percent and 25 percent respectively. The dose of zoledronic 
acid is “5 mg by intravenous infusion over at least 15 minutes once year for treatment 
and once every two years for prevention” (24,42). In a  multicenter, double-blind, 
placebo-controlled trial, 1199 men between 50 to 85 years with primary or 
hypogonadism-associated osteoporosis were randomly assigned to obtain an 
intravenous infusion of zoledronic acid (5 mg) or placebo at baseline and at 12 
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months. The results show that there is a 67% reduction in risk in the group who were 
given Zoledronic acid (Relative Risk: 0.33; 95% CI: 0.16 to 0.70; P=0.002) (48). The 
advantages of zoledronic acid are that it does not have gastrointestinal side effects as 
it administered intravenously. Also it offers less frequent dosing regimens and thus 
adherence to therapy is more (47).  
3.10.6 Side effects of bisphosphonates  
Alendronate and risedronate must be ingested before food. Hence the adverse 
effects of bisphosphonates include inflammation of the oesophagus and gastric ulcers. 
Osteonecrosis of jaw is a rare complication of bisphosphonates especially after 
intravenous administration. Visual disturbances have also been documented which if 
occurs must be immediately reported to the treating physician. Incidence of atrial 
fibrillation is also higher among patients treated with zoledronic acid when compared 
to patients on placebo (24) 
3.10.7 Parathyroid hormone  
Another FDA (Food and Drug Administration) approved drug for management 
of osteoporosis in men is Parathyroid hormone. It is a recombinant fragment of human 
parathyroid hormone (PTH) (49). It is a bone building anabolic agent which is 
administered as daily subcutaneous injections. Daily dose of 20 micrograms 
administered for eighteen months can lower the incidence of both vertebral and non-
vertebral fractures by 65 percent and 53 percent respectively (49). Studies have shown 
that PTH is a potent skeletal bone stimulator and is associated with considerable 
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increase in lumbar spine and hip bone density  (49). Teriparatide or PTH (1-84) first 
stimulates bone formation and then it is followed by an increase in bone 
resorption which is  termed as “The anabolic window” and is shown in Figure 3.12 
(50,51). 
Figure 3.10 “The anabolic window” (50) 
 
[Source: Bilezikian JP. Combination anabolic and antiresorptive therapy for 
osteoporosis: opening the anabolic window] 
Animal studies have shown an increased incidence of osteosarcoma in rats. The drug 
has doubtful safety and efficacy beyond two years of treatment (24,42). The 
contraindications for use of teriparatide are  primary hyperparathyroidism, children 
having open epiphyses, pagets disease of bone  and past history of osteosarcoma (51).  
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3.10.8 Conclusion  
Awareness about male osteoporosis is low in developing countries like India 
and this condition is still under diagnosed and under treated here. Osteoporotic 
fractures are a major public health problem. There is a paucity of data regarding the 
risk factors and their influence on bone health in an Indian context (5). Adequate 
knowledge of the  risk factors of this disease in our population will enable us to take 
right measures in order to adopt preventive measures like   avoiding smoking, reduing 
alcohol intake, and increasing level of physical activity , daily calcium intake , 
adequate intake of vitamin D  at an earlier stage (8). Further research work is 
warranted in the field of male osteoporosis so that pathogenesis is clarified (42). 
Studies are also urgently required exploring the treatment options of male 
osteoporosis.  
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4. METHODOLOGY 
 
 
4.1 Health care delivery system in CHAD   
Medical care for patients in and around Kaniyambadi block is offered by 
Community Health Department of CMC Vellore (CHAD hospital). Patients from the 
block are provided with health care at the peripheral level through a health care 
delivery system which has health workers at various levels. At the grass root level, the 
Part Time Community Health Worker (PTCHW), one for every 1000-1500 
population, visits patients in their area and report to Health aides (HA) who are in 
charge of 5000 population and they record in appropriate registers. They are 
supervised by the Public Health Nurse (PHN), one for every 15,000 population. The 
PHN visits the village once in two weeks and the HA visits every village once a week. 
This is complimented by a doctor visiting each area once a month. All patients with 
chronic diseases like diabetes mellitus and hypertension will be seen in the doctor run 
clinic and given medications. Any patient requiring investigations or hospital care will 
be referred to CHAD where the patient will be evaluated and if found to be very sick 
will be referred to CMC which is our tertiary center located around 8Km from CHAD 
for advanced medical care.  
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4.2 Study design 
This study is a cross sectional study done among the elderly men between 65 years 
and 80 years in Kaniyambadi block to find out the prevalence and risk factors for 
osteoporosis. 
4.3 Study setting  
The study was done in Kaniyambadi block. Thirteen villages were chosen by simple 
random sampling. Elderly men between the age group of 65 to 80 years were eligible 
for the study. Around fifteen to twenty patients were selected from each village by 
simple random sampling. Patient recruitment started in January 2015 and continued 
till April 2015. Data was collected by the principle investigator by a face to face 
interview using an interviewer administered questionnaire during house to house visit. 
All the participants were given an appointment for DEXA scan in CMC. They were 
picked up from the village and taken to CMC for the scan on the day of appointment. 
Blood samples also were taken during their visit to CMC to test for serum albumin, 
serum creatinine, serum calcium and phosphate.  
4.4 Inclusion criteria  
Elderly men who were between 65 and 80 years of age and not bed ridden, residing in 
the villages which are selected for the study from Kaniyambadi block was eligible for 
the study. 
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4.5 Exclusion criteria 
Bed-ridden patients were excluded from the study.  
4.6 Variables in the study 
The questionnaire had five parts  
1) Sociodemographic details such as religion, socioeconomic status, marital status  
2) FRAX-WHO fracture risk assessment tool which includes age, height ,weight, BMI 
(Body Mass Index), previous history of fracture, parent with fractured hip, current 
smoking status, h/o glucocorticoid intake, rheumatoid arthritis, any evidence of 
secondary osteoporosis, alcohol intake  
3) IPAQ (International Physical Activity Questionnaire) short version for assessment 
of the level of physical activity  
4) Dietary calcium intake (24 hour recall)  
5) Laboratory investigations for assessment of serum level of calcium, phosphate, 
albumin and creatinine  
Definition of each of the variables used in the study is given below in Table 4.1 
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Table 4.1 Definition of each of the variables used in the study  
Variable  Definition  
Height  Height of the patient measured in cm by an inch tape 
Weight  Weight of the patient measured in kg by a bathroom weighing scale  
BMI  Computed using the formulae weight in kg/height in meter ^2 
Age  Age of the patient as told by him  
SES The socioeconomic status of the patient as calculated using Kuppuswamy score  
Religion  Whether the patient was Hindu, Christian or Muslim  
Marital status  Whether the patient was married, single, separate or a widower  
Osteoporosis  BMD T-score of –2.5 or below the young normal mean for men.  
Previous fracture  A previous fracture denotes more accurately a previous fracture in adult life 
occurring spontaneously, or a fracture arising from trauma which, in a healthy 
individual, would not have resulted in a fracture.  
Parent with 
fractured hip  
a history of hip fracture in the patient's mother or father  
Current smoking  whether the patient is current smoker   
Glucocortocoids 
use  
Current use of oral glucocorticoids or has been using oral glucocorticoids for > 
3 months at a dose of prednisolone of 5 mg daily or more (or equivalent doses 
of other glucocorticoids)  
Rheumatoid 
arthritis:  
Whether the patient is a known case of Rheumatoid arthritis  
Secondary 
osteoporosis  
Any of the  diseases such as type I diabetes, osteogenesis imperfecta in adults, 
untreated long-standing hyperthyroidism, hypogonadism or, chronic 
malnutrition, or malabsorption and chronic liver disease which is associated 
with osteoporosis  
Alcohol 3 or more 
units/day  
Ingestion of 3 or more units of alcohol daily (one measure of spirits =30ml)  
Marital status  whether the patient is married/separated/widower/single  
Physical activity Physical activity assessed using the International Physical Activity 
Questionnaire (IPAQ-Short Version).  
Dietary calcium 
intake  
Calcium intake of the patient per day  
S.Calcium  The serum calcium level of the patient measured in mg/dl. During analysis was  
dichotomized as low or normal using 8.3mg/dl as cut off  
S.Phosphate The serum phosphate level of the patient measured in mg/dl 
.(normal range: 2.5-4.6mg/dl)  
S.Albumin The serum Albumin level of the patient measured in gm/dl. 
(normal range: 3.5-5 gm/dl)  
S.Creatinine The serum creatinine level of the patient measured in mg/dl. During analysis it 
was dichotomized as high or normal using 1.4mg/dl as cut off  
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4.7 Data sources and measurement 
The details for sources of each variable and details of methods of assessment are 
described in the following Table 4.2. 
Table 4.2 Sources of each variable and details of methods of assessment  
Variable  Data source /measurement  
Height  Measured during home visit using an inch tape  
Weight  Measured during home visit using a bathroom weighing scale  
BMI  Computed using the formulae weight in kg/height in meter ^2  
Age  Questionnaire  
Socioeconomic status  Questionnaire  
Religion  Questionnaire  
Marital status  Questionnaire  
Osteoporosis  Dexa 
Previous fracture  Questionnaire  
Parent with fractured hip  Questionnaire  
Current smoking  Questionnaire  
Glucocortocoids use  Questionnaire  
Rheumatoid arthritis:  Questionnaire  
Secondary osteoporosis  Questionnaire  
Alcohol 3 or more units/day  Questionnaire  
Marital status  Questionnaire  
Socioeconomic status  Questionnaire  
Physical activity Questionnaire  
Dietary calcium intake  Questionnaire  
S.Calcium Laboratory investigation  
S.Phosphate Laboratory investigation  
S.Albumin Laboratory investigation  
S.Creatinine Laboratory investigation  
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4.8 Sample size calculation  
n=4*P*Q/d^2  
where P is the prevalence of osteoporosis (5) 
P=45%  
Q=100-P=55  
d=9   
=4*45*55/9^2  
=122  
Applying a design effect of 1.5 = 183 
4.9 Data collection 
Patients who fulfilled the inclusion criteria were included in the study. The principle 
investigator conducted house visits in the thirteen villages of Kaniyambadi block 
which were chosen by simple random sampling. In each village approximately 15-20 
elderly men were chosen by simple random sampling. The principle investigator 
during the house visit filled in the interviewer administered questionnaire.  
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4.9.1 Questionnaire  
Questionnaire had five parts 
1) Sociodemographic details  
2) FRAX_WHO fracture risk assessment tool  
3) IPAQ short version for assessment of the level of physical activity  
4) Dietary calcium intake (24 hour recall)  
5) Laboratory investigations for determination of serum level of calcium, phosphate, 
albumin and creatinine. Blood sample was collected during their visit to the hospital. 
Albumin correction for calcium was done using the formulae: 
“Corrected calcium = [(4-albumin)*0.8+actual calcium]” 
Bone Mineral Density was assessed by DEXA scan. 
4.9.2 DEXA Scan  
Prior appointment was obtained for DEXA scan. The people who were recruited into 
the study were taken to CMC Vellore for dexa scan of femur and lumbar spine. In this 
study Bone mineral density was measured on a Hologic Dual energy X-Ray 
absorptiometry (DEXA) machine (Discovery A- QDR 4500) which has a one pass 
single sweep scanning system for better quality and precision.  
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4.9.3 Ascertainment of other risk factors 
4.9.3.1 Socioeconomic factors 
Factors such as education, occupation of the patient and the head of the family were 
collected. The total income of the family was also obtained during the interview. 
These were coded based on the Kuppusamy’s socioeconomic scale. The score for 
education ranged from one to seven and the score for occupation ranged from one to 
ten. SES was computed based on the Kuppusamy’s modified SES scale (2014) using 
the three variables.SES was classified into five categories namely lower, upper lower, 
lower middle, upper middle and upper.  
4.9.3.2 Body Mass Index 
Weight and height were taken at the time of home visit using a bathroom weighing 
scale and an inch tape respectively. For the purpose of analysis BMI was categorized 
into high and low taking 25 as the cut off as BMI more than 25 is defined as 
overweight.  
4.9.3.3 FRAX® 
To evaluate the fracture risk of patients WHO has developed a tool called FRAX® 
tool. This tool utilizes individual patient models that use the risks associated with 
clinical risk factors as well as bone mineral density (BMD) at the femoral neck. 
Depending on population based cohorts from Europe, North America, Asia and 
Australia the FRAX model was developed. It is computer generated and freely 
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available from the internet (Annexure 2). The FRAX algorithm gives the ten year 
probability of fracture. It gives both 10 year hip fracture probability and 10 year major 
osteoporotic fracture probability (clinical spine, forearm, hip or shoulder fracture).  
4.9.3.4 IPAQ 
IPAQ was used to assess physical activity undertaken in four domains such as 
vigorous physical activity, moderate physical activity, walking and sitting. Frequency 
(measured in days per week) and duration (time per day) for each specific type of 
activity were collected separately. The level of activity was calculated by weighting 
each activity by its energy requirements defined in METS (METS which is the 
“Metabolic Equivalent of Task” are the multiples of the resting metabolic rate) which 
gives a score in MET-minutes. MET minute was a product of the MET score and  the 
minutes performed. MET minutes score are equivalent to kilocalories for a 60Kg 
person.  
4.9.3.4.1 MET values and Formula for calculation  of Met-minutes  
 
[Source: Guidelines for Data Processing and Analysis of the International Physical Activity 
Questionnaire (IPAQ) - Short Form, Version 2.0. April 2004 (52)] 
 
“Walking MET-minutes/week  
= 3.3 * walking minutes * walking .days. 
Moderate MET-minutes/week  
= 4.0 * moderate-intensity activity minutes * moderate days 
44 
 
Vigorous MET-minutes/week  
= 8.0 * vigorous-intensity activity minutes * vigorous-intensity days” (52) 
Three levels of physical activity were defined to classify population. The categories 
are  
i) HEPA active(Health Enhancing Physical Activity) 
ii) minimally active  
iii) inactive 
Health Enhancing Physical Activity (HEPA-Category 3): This category included 
people who exceeded the minimum public health physical activity 
recommendations. People in this group will be active at least 1.5 to 2 hrs in a day. 
Subjects who fit into the following criteria were included in this group: 
i) “vigorous-intensity activity on at least 3 days achieving a minimum of at 
least 1500 MET-minutes/week OR 
ii) 7 or more days of any combination of walking, moderate-intensity or 
vigorous intensity activities achieving a minimum of at least 3000 MET-
minutes/week” (52) 
 
 
Minimally active (Category 2): The people who belonged to this category have 
physical activity above the  minimum level  recommended for adults in current public 
health recommendation.  
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Subjects fulfill at least one of the following 3 criteria: 
1) “3 or more days of vigorous activity of at least 20 minutes per day OR 
2)  5 or more days of moderate-intensity activity or walking of at least 30 minutes 
per day OR 
3)  5 or more days of any combination of walking, moderate-intensity or vigorous 
intensity activities achieving a minimum of at least 600 MET-min/week” (52). 
Inactive category: This category of people has the lowest level of physical activity. 
Individuals who did not meet criteria for category 2 or 3 were categorized as  
insufficiently active or category 1.  
4.9.3.4.2 Continuous score for IPAQ 
Another method of expressing the IPAQ score in the study was reporting it as a 
continuous score. The total MET minutes was calculated for each person and 
expressed as median MET minutes. 
A combined total physical activity MET-min/week was calculated using the formula: 
“Total physical activity MET-min/week  
=Walking + Moderate + Vigorous MET-min/week scores” (52) 
IPAQ sitting question  
It is an extra question which is not part of any scoring for total physical activity.  
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4.9.3.5 Nutritional Status  
Twenty four hour diet recall of the patient was collected by the PI at the time of data 
collection. This was performed to assess the daily calcium intake of the patient. The 
PI (Principal Investigator) was blinded regarding the BMD status of the patient at the 
time of data collection.  
4.10 Data entry and analysis 
Data entry was done in Epidata version 3.1. Analysis was done in SPSS version 16.0.  
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5. RESULTS  
5.1 Sociodemographic profile 
A total of 180 men were included in the study. The distribution of the study 
population by age is described in the table below. 
Table 5.1 Description of the study population by age 
Age group(years) Frequency Percent 
65-70 97 53.9 
71-75 54 30 
76-80 29 16.1 
Total 180 100 
Among the study population, 53.9% were in the 65 to 70 years group, 30% between 
71 to 75 years and 16.1% between 76 and 80 years.  
Table 5.2 Description of the study population by education  
Education Frequency Percent 
Nil  37 20.6 
Primary school 59 32.8 
Middle school 43 23.9 
High school  31 17.2 
Intermediate  5 2.8 
Under graduate / 
Post graduate  5 2.8 
Total 180 100 
In the study population, 77.3% had studied up to middle school or less, while 
only 2.8% had proceeded on to college education [Table 5.2].  
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Table 5.3 Description of the study population by their previous occupation 
Category Frequency Percent 
 Unskilled  49 27.2 
Semiskilled  7 3.9 
Skilled  25 13.9 
Farmer  87 48.3 
Semi professional 1 0.6 
Professional   11 6.1 
Total 180 100 
 
The highest proportion of the study population were in agriculture (48.3%) and 
unskilled or manual labour (27.2%)  [Table 5.3]. 
Table 5.4  Description of the study population by marital status  
Category  Frequency Percent 
Married  161 89.4 
Single  2 1.1 
Separated  1 0.6 
Widower  16 8.9 
Total  180  100 
 
Almost 90% of the subjects were married, while 9% were widowed [Table 5.4]. 
Religion - 99% of the subjects were Hindu by religion. 
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Significant past medical history and life style  
30% of the subjects had a previous history of fracture. 6% of the subject had a parent 
who fractured a hip. 22.8% of the subjects were active smokers. 10.6% of the subjects 
consumed 3 or more units of alcohol per day.  
Table 5.5 Description of the study population by socioeconomic status  
Category  Frequency Percent 
Lower  0 0 
Upper lower  68 37.9 
Lower middle  71 39.4 
Upper middle  35 19.4 
Upper  6 3.3 
Total  180 100 
None of the subjects were in the lower socioeconomic group and majority were in the 
lower middle (39.4%) and upper lower (37.8%) categories respectively [Table 5.5].  
5.2 Body Mass Index  
Table 5.6 Distribution of BMI among the study population  
BMI 
(Kg/m2) 
Frequency Percent 
≤18.49  32 17.8 
18.5-24.99  104 57.8 
25.0-29.99 36 20.0 
≥30  8 4.4 
Total  180 100 
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BMI was categorized into underweight (≤18.49), normal (18.5-24.99), over 
weight (25.0-29.99) and obese (≥30). 57.8% had a normal BMI, 17.8% were 
underweight, 20% were overweight and 4.4% were obese [Table 5.6].  
5.3 Physical activity  
Table 5.7   Distribution of physical activity among the study population  
Category Frequency Percent 
Inactive 
 (0-599MET mins/week) 
17 9.4 
Minimally active  
(600-2999MET mins /week) 
53 29.4 
Health enhancing physical activity 
 (≥3000MET min/ week) 
110 61.1 
Physical activity was analyzed using the IPAQ questionnaire and MET minutes 
per week calculated for each subject. It was categorized into inactive group (0-
599MET minutes per week); minimally active (600-2999MET minutes per week) and 
Health enhancing physical activity (≥3000 MET minutes per week).  
61.1% of the subjects were in the Heath enhancing physical activity (HEPA) 
category, 29.4% in the minimally active category and 9.4% in the inactive category 
[Table 5.7 ].  
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Table 5.8  Description of some of the study variables 
Category  Mean (Std Dev) Median 
Age (years) 70.89(4.54) 70 
Weight (kg) 59.79(13.14) 59.25 
Height (cm) 164.18(5.82) 164.25 
BMI(Kg/m²) 22.14(4.05) 21.75 
MET minutes per   week 6679(6829) 4158 
Daily dietary calcium intake(mg) 188(4.36) 180 
 
The mean age of the subjects were 70.89 years (SD: 4.54years) and the median 
was 70years. The mean weight and standard deviation was 59.79Kg and 13.14Kg 
respectively. The median weight was 59. 25Kg. The mean height was 164.18cm and 
the standard deviation was 5.82cm. The median height was 164.25cm. The mean BMI 
was 22.14Kg/m² with a standard deviation of 4.05Kg/m² and a median of 21.75Kg/m² 
[Table 5.8 ].  
5.4 Dietary calcium intake  
The daily calcium intake of the subjects was assessed using a 24 hour dietary 
recall questionnaire. The average daily calcium intake was 188mg per day with a 
standard deviation was 4.36mg/day. The median was 180mg. This is much lower than 
the RDA (Recommended Dietary Allowance) which is 1200mg/day.  
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5.5 Biochemical parameters  
Table 5.9  Description of Biochemical Parameters  
Variable Mean(SD) Median 
Serum Calcium  
 (Normal Range:8.3-10.4mg/dl)  8.821(0.497) 8.79 
Serum Phosphorus 
(Normal Range:2.5-4.6mg/dl)  3.32(0.833) 3.20 
Serum Albumin 
(Normal Range:3.5-5g/dl)  4.19(0.38) 4.20 
Serum Creatinine  
(Normal Range:0.7-1.4 mg/dl)  0.97(0.34) 0.90 
BMD Lumbar Spine(g/cm²)  0.967(0.215) 0.937 
BMD Femoral neck(g/cm²)  0.702(0.157) 0.705 
 
The serum levels of Calcium, Phosphorous, Albumin and Creatinine were 
assessed. The mean serum calcium was 8.821mg/dl (SD: 0.497) with a median of 
8.79mg/dl. The mean and SD of serum phosphorous was 3.32(0.833) mg/dl and the 
median was 3.20 mg/dl. The mean and standard deviation of serum albumin was 
4.19(0.38) mg/dl and the median was 4.20mg/dl. The mean and standard deviation of 
serum creatinine is 0.97(0.34) mg/dl and the median is 0.90 mg/dl. The mean and 
standard deviation of Bone Mineral Density for lumbar spine was 0.967(0.215) g/cm2 
and the median was0.937g/cm2. The mean and SD of Bone Mineral Density for 
femoral neck was 0.702 g/cm2 and 0.157 g/cm2 respectively. The median BMD of 
femoral neck was 0.705 g/cm2   [Table 5. 9]. 
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5.6 T-score for hip and lumbar spine  
The histograms for T score for hip and lumbar spine were found to be normally 
distributed. [Figure 5.1& 5.2] 
Figure 5.1 Histogram of hip T-score
 
Figure 5.2 Histogram of lumbar spine T- score
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5.7 Prevalence of osteoporosis 
Figure 5.3 Prevalence of osteoporosis in hip and lumbar spine     
 
In the hip region 25.6% had normal BMD, while 53.3% were osteopenic and 21.1% 
had osteoporosis. In the lumbar spine, 41.1% had normal BMD, 34.4% were 
osteopenic and 24.4% were osteoporotic [Figure 5.3]. 
• Proportion of subjects with normal BMD in both hip and lumbar spine: 
16.7%(n=30) 
• Proportion of subjects with osteopenia in both the sites: 19.4%(n=35)  
• Proportion of subjects with osteoporosis in both the sites: 11.1%(n=20)  
• Prevalence of osteoporosis in either hip or lumbar spine or both: 34.4% 
(95%CI: 27.31% to 41.48%) 
• Prevalence of osteopenia alone in either hip or lumbar spine or both: 48.9 % 
(95%CI: 41.45% to 56.35%) 
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5.8 Fracture risk assessment 
A 10 year major osteoporotic fracture (in the proximal part of the humerus, the wrist, 
or the hip or a clinical vertebral fracture) and hip fracture risk assessment were done 
in subjects with osteopenia. It was calculated by the FRAX WHO fracture risk 
assessment tool which utilizes clinical data such as age, gender, history of smoking, 
alcoholism, use of steroids, history of previous fracture, and history of parent hip 
fracture along with the femoral neck BMD. 
It was found that none of the 88 subjects with osteopenia have a major osteoporotic 
fracture risk of more than 20% while 6 (6.8%) have >3% chance for hip fracture.  
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5.9 Pearson’s/spearman’s correlation between BMD and various risk factors 
 
 Table 5.10  Correlation coefficient between BMD and various risk factors 
Variable 
Femoral neck BMD Hip BMD Lumbar spine BMD 
Correlation 
coefficient 
p value 
Correlation 
coefficient 
p  
value 
Correlation 
coefficient 
p value 
Weight 0.396 <0.001 0.421 < 0.001 0.404 < 0.001 
Height 0.224 0.002 0.132 0.072 0.130 0.082 
Age -0.212 0.004 -0.145 0.052 0.17 0.825 
BMI 0.375 < 0.001 0.428 < 0.001 0.393 < 0.001 
SES 0.078 0.300 0.111 0.137 0.058 0.440 
Serum Calcium 0.107 0.154 0.103 0.167 0.059 0.431 
Serum phosphate -0.025 0.744 -0.080 0.288 -0.044 0.554 
Serum creatinine -0.037 0.618 -0.006 0.941 0.162 0.030 
Serum albumin 0.244 0.001 0.249 0.001 0.262 < 0.001 
Total physical 
activity(MET 
minutes per week) 
0.120* 0.110 0.133 0.075 -0.003 0.964 
Dietary calcium 
intake per day 
0.115 0.125 0.132 0.078 0.108 0.149 
* Spearman’s correlation  
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Correlation coefficient was calculated for various factors such as weight, height, age, 
BMI, socioeconomic status, serum levels of calcium, phosphate, creatinine, albumin, 
total physical activity and dietary calcium with femoral neck BMD, hip BMD and 
lumbar spine BMD.  
It was found that weight, BMI and serum albumin positively correlated with BMD in 
all the three areas (hip, femoral neck and lumbar spine) which was statistically 
significant.  
Statistically significant positive correlation between height and BMD was found only 
in the femoral neck [Table 5.10].  
Age was found to be negatively correlated with femoral neck BMD and it was 
statistically significant. There was a statistically significant correlation between serum 
creatinine and lumbar spine BMD.  
There was no statistically significant correlation between BMD and Socioeconomic 
status, serum calcium, serum phosphorous, total physical activity (MET minutes per 
week) or daily dietary calcium intake.  
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Figure 5.4 Scatter plot between hip BMD and weight  
 
There is significant positive correlation between BMD and weight with Pearson’s 
correlation coefficient of 0.421 and a p value < 0.001[Figure 5. 4] 
Figure 5.5 Scatter plot between hip BMD and BMI 
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Similarly there is positive correlation between hip BMD and BMI with a Pearson’s 
correlation of 0.428 and a p value of < 0.001 [Figure 5.5]. 
 
Figure 5.6 Scatter plot between lumbar spine BMD and Serum Albumin   
 
On plotting a scatter plot between lumbar spine BMD and serum albumin, it 
was seen that there was a positive correlation between the two with a Pearson’s 
correlation coefficient of 0.262 and a p value of < 0.001 [Figure 5.6].  
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5.10 UNIVARIATE ANALYSIS  
Associations between osteoporosis and various risk factors 
Table 5.11  Association between osteoporosis and sociodemographic factors  
RISK FACTORS Osteoporosis Present  
No 
Osteoporosis  
OR 
(95% CI) 
P  
VALUE 
Age     
Age up to 70 32(33%) 65(67%) 0.870 
(0.470-1.611) 0.657 Age >70 30(36.1%) 53(63.9%) 
SES 
Lower SES 24(35.3%) 44(64.7%) 1.062 
(0.564-2.000) 0.852 Middle and upper SES 38(33.9%) 74(66.1%) 
Marital status 
Separated/widower/divorced 11(57.9%) 8(42.1%) 2.966 
(1.125-7.818) 0.023 Currently married 51(31.7%) 110(68.3%) 
Education 
Nil 17(45.9%) 20(54.1%) 1.851 
(0.886-3.867) 0.099 Literate 45(31.5%) 98(68.5%) 
Previous occupation 
Unskilled 17(34.7%) 32(65.3%) 1.015 
(0.509-2.024) 0.966 Semiskilled and above 45(34.4%) 86(65.6%) 
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Univariate analysis between age and osteoporosis was computed. The cut off 
for age was taken as 70 years as it was the median age and it was found that there is 
no statistically significant association between age and osteoporosis [Odds ratio and 
95%CI:0.870 (0.470-1.611) p value=0.657].  
 Similarly socioeconomic status was dichotomized into low SES and 
middle/upper SES and it was found that there is no statistically significant association 
between SES and osteoporosis [Odds ratio and 95%CI: 1.062 (0.564-2.000) p value 
=0.852].  
Previous occupation of the subjects were dichotomized into unskilled and 
semiskilled or above and it was found that there is no statistically significant 
association between the two [Odds ratio and 95%CI: 1.015(0.509-2.024) and p 
value=0.966]. 
Marital status was dichotomized into currently married and 
separated/widower/divorced and it showed a statistically significant association 
between the two suggesting that there is higher chance of osteoporosis in subjects 
who are separated/widower/divorced than those who are currently married [Odds ratio 
and 95% CI: 2.966 (1.125-7.818) and a p value of 0.023]. 
Education was categorized into no education and literate. It was found that 
there is a higher chance of osteoporosis in people who are not educated than those 
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who are educated [Odds Ratio and 95% CI: 1.851 (0.886-3.867)], however it was not 
statistically significant (p value =0.099) [Table 5.11].  
Weight was categorized into less than 60 kg and more than 60 kg as the cut off 
based on the median. It was found that men weighing less than 60 kg had a 4.143 
times increased risk for osteoporosis when compared to men who weighed more than 
60 kg and it was statistically significant [Odds Ratio and 95% CI: 4.143 (2.121-8.093) 
and p value <0.001] 
 
Chi square test was performed between BMI and osteoporosis. BMI was 
categorized into underweight (BMI<18.5 Kg/m²), normal (BMI 18.5 Kg/m²-25.0 
Kg/m²) and overweight/obese (BMI≥25.0 Kg/m²). It was found that there was a 
statistically significant difference between the BMI categories and osteoporosis with a 
p value of <0.001 [Table 5.12].  
 
 
Table 5.12 Association between BMI and osteoporosis 
 
Category of 
BMI (Kg/m²) 
Osteoporosis 
present No Osteoporosis Chi square p value 
<18.5 23 (71.9%) 9 (28.1%) 
28.26 <0.001 18.5-25.0 32 (30.8%) 72 (69.2%) 
≥25 .0 7 (15.9%) 37 (84.1%) 
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Association between osteoporosis and biochemical factors 
Table 5.13  Association between osteoporosis and biochemical factors 
RISK FACTORS Osteoporosis Present  
No 
Osteoporosis  
OR  
(95% CI) 
P  
VALUE 
Serum albumin (g/dl) 
  
  
Serum  Albumin<=4.0 29(48.8%) 33(53.2%) 2.264 
(1.193-4.296) 
0.012 
Serum albumin>4.0 33(28%) 85(72%) 
Serum phosphate (mg/dl) 
Phosphorus >2.5 55(34%) 107(66%) 0.808 
(0.297-2.200) 
0.676 
Phosphorus ≤2.5 7(38.9%) 11(61.1%) 
Serum Creatinine (mg/dl) 
S.creatinine > 1.4 5(38.5%) 8(61.5%) 1.206 
(0.377-3.856) 
0.768 
 S.creatinine  ≤ 1.4 57(34.1%) 110(65.9%) 
Corrected serum calcium (mg/dl) 
Corrected calcium <= 8.20 5(41.7%) 7(58.3%) 1.416 
(0.430-4.662) 
0.566 
    Corrected calcium  > 8.20 56(33.5%) 111(66.5%) 
 
Serum albumin was dichotomized into less than 4g/dl and more than 4 g/dl and 
it was found that people with a low serum albumin had a 2.26 times increased risk for 
osteoporosis than people who had serum albumin more than 4 g/dl and it was 
statistically significant [Odds Ratio and 95%CI: 2.264 (1.193-4.296) and p value: 
0.012].  
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However there was no statistically significant association between serum 
creatinine [Odds Ratio and 95% CI: 1.206 (0.377-3.856) and p value:0.768], serum 
Phosphate[Odds Ratio and 95% CI: 0.808 (0.297-2.200) and p value:0.676],  serum 
calcium [Odds Ratio and 95% CI: 1.416 (0.430-4.662) and p value:0.566] and 
physical activity[Odds Ratio and 95% CI:1.096 (0.584-2.056) and p value:0.775] with 
osteoporosis.  Results of the univariate analysis of the various biochemical parameters 
are summarized in Table 5.13.  
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Association between osteoporosis and other risk factors 
Table 5.14 Association between osteoporosis and other risk factors 
RISK FACTORS Osteoporosis Present  
No 
Osteoporosis  
OR  
(95% CI) 
P  
VALUE 
Health enhancing physical activity 
No Health Enhancing 
Physical Activity 25(35.7%) 45(64.3%) 1.096 
(0.584-
2.056) 
0.775 
Health enhancing physical 
activity present 37(33.6%) 73(66.4%) 
Smoking 
Smoking  - Yes 18(43.9%) 23(56.1%) 1.69 
(0.828-
3.447) 
0.147 
Smoking - No 44(31.7%) 95(68.3%) 
Previous fracture 
Yes 19(35.2%) 35(64.8%) 1.048 
(0.537-
2.046) 
0.891 
No 43(34.1%) 83(65.9%) 
Parent hip fracture 
Yes 3(30%) 7(70%) 0.806 
(0.201-
3.234) 
0.761 
No 59(34.7%) 111(65.3%) 
Alcohol 
Alcohol intake  - Yes 7(36.8%) 12(63.2%) 1.124 
(0.419-
3.018) 
0.816 
Alcohol intake- No 55(34.2%) 106(65.8%) 
BMI 
BMI <25 55(40.4%) 81(59.6%) 3.589 
(1.493-
8.631) 
0.003 
BMI>=25   37(84.1%) 
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BMI was dichotomized into <18.5Kg/m2 and ≥18.5Kg/m2 and it was found 
that under weight subjects have a seven times higher risk for osteoporosis than 
normal/overweight/obese subjects and it is statistically significant.[odds ratio and 
95%  CI:  7.142 (3.04 to 16.76) and p value: <0.001]. 
Alcohol intake was not significantly associated with osteoporosis [Odds Ratio 
and 95% CI: 1.124 (0.419-3.018) and p value: 0.816].   
Similarly smoking [Odds ratio and 95% CI: 1.69 (0.828-3.447) ;p value:0.147]   
history of previous fracture[Odds ratio and 95% CI :1.048 (0.537-2.046)  and p 
value=0.891] and history hip fracture in parent [Odds ratio and 95%CI : 0.806 (0.201-
3.234) ;p value:0.761] also were not significantly associated with osteoporosis [ Table 
5.14] 
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5.11 Linear regression  
Association between femoral neck BMD and various risk factors  
Linear regression was performed taking BMD of femoral neck and lumbar 
spine as the dependent variable and other factors such as age, BMI, Serum albumin, 
marital status and education as independent variables. 
Table 5.15  Linear regression between femoral neck BMD and risk factors for 
osteoporosis 
Variable Beta coefficient p value 95% CI 
Age -0.012 0.379 -0.040 to 0.015 
BMI 0.074 <0.001 0.046 to 0.102 
Serum albumin 0.449 0.007 0.127 to 0.772 
Marital status -0.062 0.761 -0.462 to 0.338 
Education 0.215 0.162 -0.087 to 0.516 
 
Table 5.15 shows the linear regression between femoral neck BMD and the 
various risk factors for osteoporosis. As age increases by one year the femoral neck 
BMD decreases by 0.012 g/cm2 ,however it is not statistically significant(p 
value=0.379) 
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There was a statistically significant association between femoral neck BMD 
and BMI. As BMI increases by 1 Kg/m2, femoral neck BMD increases by 0.074 
g/cm2 and it was statistically significant with a p value of <0.001.  
Similarly there was a statistically significant association between femoral neck 
BMD and serum albumin. As serum albumin increases by 1g/dl, femoral neck BMD 
increases by 0.449g/cm2 and it is statistically significant (p value=0.007). 
Marital status (p value=0.761) and education of the subject (p value=0.162) 
were not significantly associated with femoral neck BMD.  
Association between lumbar spine BMD and various risk factors  
Linear regression was performed between lumbar spine BMD and various other risk 
factors for osteoporosis [Table 5.16]. 
Table 5.16  Linear regression between lumbar spine BMD and risk factors for 
osteoporosis 
Variable Beta coefficient p value 95% CI 
Age 0.006 0.068 0.000 to 0.012 
BMI 0.018 <0.001 0.012 to 0.025 
Serum albumin 0.120 0.002 0.044 to 0.196 
Marital status -0.060 0.213 -0.154 to 0.035 
Education 0.035 0.335 -0.036 to 0.106 
 
69 
 
 
BMI and serum albumin were significantly associated with lumbar spine BMD. As 
BMI increases by 1kg/m2 lumbar spine BMD increases by 0.018g/cm2 (p value is < 
0.001).  
Similarly as serum albumin increases by 1g/dl lumbar spine BMD increases by 0.120 
g/cm2 (p value=0.002).  
Age (p value=0.068), marital status (p value=0.213) and education (p value=0.335) 
were not significantly associated with lumbar spine BMD.  
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5.12 Logistic regression 
Table 5.17  Multiple logistic regression showing factors affecting osteoporosis 
 
Variable Osteoporosis present 
No 
osteoporosis 
Unadjusted 
OR 
(95% CI) 
p  
value 
Adjusted 
OR 
(95% CI) 
p 
value 
BMI 
BMI<18.5 23(71.9%) 9(28.1%) 7.142 
(3.04 to 16.76) 
 
<0.001 8.389 (3.354-20.98) <0.001 
BMI≥18.5 39(26.4%) 109(73.6%) 
Age 
Age ≥70 35(34.7%) 66(65.3%) 
1.021 
(0.550-1.898) 0.947 
0.918 
(0.458-1.841) 0.810 
Age <70 27(34.2%) 52(65.8%) 
Marital status 
Separated/ 
widowed/ 
divorced 
11(57.9%) 8(42.1%) 
2.966 
(1.125-7.818) 0.023 
2.457 
(0.792-7.628) 0.120 
Married 51(31.7%) 110 (68.3%) 
Education 
Nil 17(45.9%) 20(54.1%) 
1.851 
(0.886-3.867) 0.099 
2.431 
(1.050-5.628) 0.038 
Literate 45(31.5%) 98(68.5%) 
Serum Albumin 
Albumin ≤4 29(48.8%) 33(53.2%) 
2.264 
(1.193-4.296) 0.012 
2.569 
(1.253-5.267) 0.010 
Albumin >4 33(28%) 85(72%) 
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Multiple logistic regression was performed taking all the variables which had a 
p value less than 0.10 in the univariate analysis and age was also included as it is a 
physiological factor which can influence bone mineral density. Results of logistic 
regression are summarized in the Table 5.17. 
After adjusting for the possible confounding factors, it was found that literacy, 
BMI and serum albumin were still significantly associated with osteoporosis.  
People who had no education had a 2.43 times increased risk for development 
of osteoporosis when compared to educated men (95% CI and p value: 1.050-5.628; 
0.038).  
Men who had a BMI less than 18.5 had an 8.3 times increased risk for 
osteoporosis with a 95% confidence interval between 3.354-20.98 and p value of < 
0.001. 
Serum albumin level of less than 4g/dl had a 2.56 times increased risk for 
osteoporosis with a 95% confidence interval of 1.253-5.267 and a p value of 0.010.  
Age [Odds Ratio and 95%CI: 0.918 (0.458-1.841); p value: 0.810] and marital 
status [Odds Ratio and 95%CI:2.457 (0.792-7.628); p value: 0.120] did not have any 
significant association with osteoporosis.  
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6. DISCUSSION  
Osteoporosis has mostly been considered to be a problem affecting women. 
However, recent evidence suggests that male osteoporosis is an important emerging 
public health problem. This study was aimed at exploring the prevalence of 
osteoporosis and the risk factors for the same among elderly ambulatory men in South 
India. This was a community based study, thus the results is a true representation of 
the prevalence in the community.  
Prevalence of osteoporosis 
The table given below [Table 6.1] shows a comparison between the present study and 
earlier studies on the prevalence of osteoporosis in men. 
Table 6.1 Comparison of prevalence of osteoporosis in men 
Study Age group 
studied (years ) Prevalence 
Melton et al (14) >50 19% 
Agarwal et al (53) >50 8.5% 
Shetty et al (5) >60 45% 
Present study 65-80 34.4% 
In our study, about one third of men [34.4% (95%CI: 27.31% to 41.48%)] had 
osteoporosis at any one site, either hip or lumbar spine. The prevalence of men with 
osteopenia was also high in this study. One in every two patients had osteopenia in at 
least one site [48.9% (95%CI: 41.45% to 56.35%)]. Only 16.7% of the patients had a 
normal bone mineral density in both the sites.  
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Prevalence of osteoporosis in healthy Indian men above 50 years of age as 
published in a study done by Agarwal et al was 8.5%. The prevalence of osteopenia in 
the same study was  42% (53). Another study done in by Shetty et al in South India 
the reported prevalence of osteoporosis was 20% in men above 50 years (5).The mean 
age of the population of that study was 58.8years when compared to 70.89 years in 
the current study which might be one of the factors contributing to the difference in 
prevalence.  However, the prevalence of osteoporosis in men above 60 years in the 
same study (Shetty et al) was 45%. A study done by Melton et al in Rochester showed 
a prevalence rate of osteoporosis in men above 50 years to be 19% (14). 
The estimated bone loss in men with aging is 1percent per year (54). 
Trabecular thinning in men is attributed to bone remodeling with aging (55). Bone 
Mineral Density in men start to decline in men from 30 to 40 years of age (5). This 
study showed a negative correlation between age and BMD in the femoral neck 
[Pearson’s correlation coefficient=-0.212 and p value=0.0.004].   
Body Mass Index 
Table 6.2 Comparison of prevalence of osteoporosis in different BMI categories 
BMI Normal Overweight Obese 
Nottingham fracture 
liaison study (56) 40.40% 24.90% 13.40% 
Present study 57.80% 20% 4.40% 
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In a cross sectional study which used data collected from the Nottingham 
Fracture Liaison Service, the prevalence of osteoporosis varied across different 
categories of BMI. It was found to be 13.4%, 24.9%, and 40.4% in the obese, 
overweight and normal category respectively (56) [Table 6.2].  Distribution of 
prevalence of osteoporosis in different BMI groups in the present study was 4.4%, 
20% and 57.8% in the obese, overweight and normal category respectively. The 
difference in prevalence between different populations could be due to factors such as 
genetic, dietary and environment differences.  Table 6.3 summarizes the findings from 
different studies which assessed the association between BMI and osteoporosis. 
   
Table 6.3 Association between BMI and osteoporosis in different studies summarized 
Study Study subjects Finding  
Salamat et al(57) 230 men 50-79 years old 
Obesity decreased the risk for 
osteoporosis 
The Framingham 
study (58) 
Elderly male and female 
participants  of the 
Framingham osteoporosis 
study 
Recent weight and BMI 
explained variance in BMD 
in men 
Fawzy et al (59) Men and women 25 to 80years 
Lower BMI is a risk factor 
for low BMD. 
Nguyen et al(60) 1075 women and 690 men 
aged 60 or above 
Higher weight or BMI  
associated with higher BMD 
Present study 
180 men  
65 to 80 years 
Men with BMI less than 18.5 
had an 8.3 times increased 
risk for osteoporosis 
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This study showed an increase in BMD with increasing BMI in keeping with several 
other studies. In an Iranian study which investigated the relation between BMI, weight 
and BMD in Iranian men it was found that the age-adjusted odds ratio was 4.4 for 
men with a BMI <25 in comparison to men with BMI more than 25 (57). In another 
study done by Nguyen et al to assess the effect of dietary calcium, physical activity 
and body mass index on osteoporosis it was found that , among subjects who 
belonged to the lowest tertile of BMI, quadriceps strength and dietary calcium intake, 
40% of the men were classified as osteoporotic (60). In a study done in Australia 
among  Iranian women it was found that advancing age, low BMI and smoking were 
independently associated with lumbar spine and femoral neck BMD (61). A study 
done at University hospitals Coventry and Warwickshire (UK) showed that the 
beneficial effect of BMI on bone mineral density exists up to a BMI of 
35Kg/m2beyond which there is no further increase in BMD (62). The Framingham 
study suggested that the load on the weight bearing bones is responsible for the strong 
effect of weight on Bone Mineral Density (63). The other factors which are 
responsible are increased peak bone mass and higher circulating estradiol in the blood 
(5). However, studies done among urban black south African women have shown that 
lean body mass, and not fat mass is favorable for bone health(64).Visceral Adipose 
Tissue (VAT) is deleterious to bone health. The characteristic features of male obesity 
such as decreased growth hormone and testosterone may be detrimental whereas 
estradiol is protective (65).  
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Serum albumin 
Table 6.4 Association of BMD and serum albumin in different studies summarized  
Study Finding 
Monaco et al (66) Positive correlation of BMD and serum albumin 
Rancho Bernado study (67) No association between the BMD and serum albumin 
Present study Low serum albumin is an independent risk factor for 
osteoporosis 
 
Protein deficiency is harmful for bone health. However the association 
between BMD and serum albumin is debatable. This study showed that the low serum 
albumin is an independent risk factor for osteoporosis (Odds Ratio and 95%CI: 2.56; 
1.253-5.267 and a p value of 0.010.). Monaco et al found a positive correlation 
between albumin and BMD measured in the total femur (r = 0.50, p < 0.01), femur 
neck (r = 0.52, p < 0.01), intertrochanteric area (r = 0.52, p < 0.01) and Ward's 
triangle (r = 0.49, p < 0.01) in men (66). However in the Rancho Bernado study which 
investigated the relation between serum albumin and BMD in community dwelling 
white men and women between the age group of 50 to 95yeras, it was found that there 
was no age independent association between BMD and serum albumin (67). Table 6.4 
summarizes the findings from different studies which assessed the association 
between serum albumin and osteoporosis.  
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Univariate analysis in this study showed that people who were either single, 
divorced or widowed were at higher risk for development for osteoporosis [Odds 
Ratio and 95%CI:2.966 (1.125-7.818) and a p value of 0.023]. However this 
association was not significant after adjusting for the potential confounding factors. 
This finding is in corroboration with finding from the systematic review which 
showed that there is strong evidence for association between being married or living 
with someone and reduced risk for osteoporotic fractures (68). 
In a cross sectional study which evaluated the association between poverty, 
bone density, fragility fractures and metabolic syndrome in Southern European 
women, it was found that lower socioeconomic status was associated with lower 
levels of BMD at the lumbar spine and higher prevalence of fragility fractures (69). In 
our study even though there was no statistically significant association between 
osteoporosis and socioeconomic status, it was found that there is significant 
association between education of the patient and development of osteoporosis. 
Osteoporosis was found more in people with no education and it was statistically 
significant [Odds Ratio and 95%CI: 2.431(1.050-5.628)]. In a systematic review 
which evaluated the evidence of low socioeconomic status as an independent risk 
factor for osteoporosis, it was found that there is contradictory evidence for the 
relation between osteoporotic fractures and level of income and education (68). 
Another systematic review which assessed the association SES status and BMD in 
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adults it was evident that there is a positive association between educational 
attainment and BMD in women (70).  
Table 6.5 Association between physical activity and BMD from different studies 
summarized 
Study Findings 
Nguyen et al  (56) Physical activity index was not significantly associated 
with femoral neck BMD in men 
Moayyaeri et al (71) Moderate to vigorous physical activity was associated 
with 45% risk reduction for hip fracture in men 
Present study No association between physical activity and osteoporosis 
 
 Physical activity and osteoporosis did not have any association in this study. In 
a review article which assessed the causal association between physical activity and 
osteoporotic fractures, it was evident that moderate to vigorous physical activity was 
associated with 45% (95%CI:31%-56%) risk reduction for hip fracture in men (71). 
However positive effect of physical activity on BMD is of doubtful magnitude for 
prevention of fracture risk (71) . Review of cross sectional studies shows that there is 
a positive correlation between BMD and exercise, and interventional studies suggest 
that high impact exercise is beneficial in increasing BMD (72).  The findings from 
different studies which assessed the association between physical activity and 
osteoporosis are summarized in Table 6.5. 
Smoking did not have any significant association with osteoporosis in this 
study. This was in contradiction to a meta-analysis investigating the relation between 
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smoking and osteoporosis which revealed that current smokers had reduced bone 
mass and increased fracture risk at the age of 50 years and above and this association 
remained significant even after adjusting for age, sex , body weight and years since 
menopause (73).  
This study failed to find any significant association between alcohol 
consumption and the development of osteoporosis, as opposed to studies which 
suggest that alcoholism disrupts the calcium and bone homeostasis which results in 
decreased  BMD and lead to fragility fractures (74). Ethanol may lead to osteoblastic 
dysfunction which causes reduced bone formation and mineralization (75).  
In comparison with women, elderly men have more risk factors for 
osteoporosis and is associated with three to four times higher mortality in case of hip 
fractures (76,77). The financial burden associated with osteoporotic fracture is not 
only borne by the family of the patient but the country as a whole (5,78). Apart from 
the direct cost incurred on the treatment of these fractures it is essential to include the 
indirect cost in terms of large man hours lost by the patient as well as the care giver 
which is particularly important in developing countries like India (5,79). 
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7. LIMITATIONS  
 
 
Of the several tools available to assess the physical activity, IPAQ which 
was suitable for use in the elderly, highly overestimates the level of physical 
activity and hence may not be the best tool to be used.  
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8. SUMMARY AND CONCLUSIONS  
.  
Osteoporosis is an important cause of fracture in elderly men. Although the 
morbidity, mortality, and costs of osteoporosis have been well established in post 
menopausal women and elderly men, these consequences in older men have not been 
well studied in an Indian context. In our study we assessed the prevalence and risk 
factors for osteoporosis among elderly men. We studied 180 men between the age 
group of 65 to 80 years from Kaniyambadi block by simple random sampling. We 
found that elderly men have a high prevalence of osteoporosis. Prevalence of 
osteoporosis in elderly men in South India was 34.4% (95%CI: 27.31% to 41.48%) 
and the prevalence of osteopenia was 48.9% (95%CI: 41.45% to 56.35%). Low Body 
Mass Index (BMI), low serum albumin and lack of education were significantly 
associated with osteoporosis. Smoking, alcohol consumption, serum calcium, 
phosphate, creatinine, socioeconomic status, and previous history of fracture, were not 
significantly associated with osteoporosis.  
In the coming years there will be an increase in the prevalence of osteoporosis 
owing to the aging population of India. As this is a silent disease which progresses to 
fracture without any symptoms, it is important to keep in mind the probable outcomes 
of fall in the elderly and devise strategies to prevent or reduce the impact of falls in 
this age group.  
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9. RECOMMENDATIONS  
 
 
Osteoporosis is still under diagnosed in developing countries like India. 
Much work needs to be done in this field to create awareness regarding the 
disease which will be the first step in tackling this problem. The truth that one in 
three  of all the hip fractures take place in men and that men have  twofold 
increased risk of  dying within a year after hip fracture is not given much 
consideration (80). Serious contemplation of the consequences of fracture in 
elderly men by clinicians and patients is the need of the hour 
• We recommend screening of elderly men with high risk factors such as low 
BMI and low albumin levels for osteoporosis.  
• Men should be encouraged to maintain adequate BMI to prevent the 
development of osteoporosis  
• Food with high calcium and protein  should be included in the diet of the 
elderly  
• Calcium supplementation in men should be encouraged to prevent osteoporotic 
fracture  
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Annexure 1 
 
1. NAME  
2. ID NO.  
3. VILLAGE  
4. RELIGION   
5. EDUCATION   
6. Highest education  
7. Occupation   
8. Highest occupation   
9. INCOME/month  
10. MARITAL STATUS Married Single Separated Widower  
 
 
 
 
  
1 S.CALCIUM  
2 S.PHOSPHATE  
3 s.vitamin D  
4 S.CREATININE  
5 S.ALBUMIN  
 
1. AGE /DATE OF BIRTH  
2. WEIGHT (Kg)  
3. HEIGHT(cm)  
4. PREV. FRACTURE  NO YES 
5. PARENT FRACTURED HIP NO YES 
6. CURRENT SMOKING  NO YES 
7. GLUCOCORTICOIDS  NO YES 
8. RHEUMATOID ARTHRITIS  NO YES 
9. SECONDARY OSTEOPOROSIS  NO YES 
10. ALCOHOL 3 OR MORE UNITS/DAY NO YES  
11. FEMORAL NECK BMD(g/cm2)   
FRAX-WHO FRACTURE RISK ASSESSMENT TOOL 
SOCIODEMOGRAPHIC DETAILS 
LABORATORY INVESTIGATIONS 
II 
 
 
Short Last 7 Days Telephone IPAQ 
 
READ:  I am going to ask you about the time you spent being physically active 
in the last 7 days. Please answer each question even if you do not consider 
yourself to be an active person.  Think about the activities you do at work, as 
part of your house and yard work, to get from place to place, and in your spare 
time for recreation, exercise or sport. 
READ:  Now, think about all the vigorous activities which take hard physical effort 
that you did in the last 7 days.  Vigorous activities make you breathe much harder 
than normal and may include heavy lifting, digging, aerobics, or fast bicycling.  Think 
only about those physical activities that you did for at least 10 minutes at a time. 
 
1. During the last 7 days, on how many days did you do vigorous physical activities? 
 _____  Days per week [VDAY; Range 0-7, 8,9]       
  8. Don't Know/Not Sure   
  9. Refused 
 
 [Interviewer clarification: Think only about those physical activities that you do for 
at least 10 minutes at a time.] 
 
[Interviewer note: If respondent answers zero, refuses or does not know, skip to 
Question 3] 
III 
 
 
2. How much time did you usually spend doing vigorous physical activities on one of 
those days?  
 __ __  Hours per day [VDHRS; Range: 0-16]  
 __ __ __ Minutes per day   [VDMIN; Range: 0-960, 998, 999]     
  998. Don't Know/Not Sure   
  999. Refused  
 
[Interviewer clarification: Think only about those physical activities you do for at 
least 10 minutes at a time.] 
 
[Interviewer probe: An average time for one of the days on which you do vigorous 
activity is being sought. If the respondent can't answer because the pattern of time 
spent varies widely from day to day, ask: "How much time in total would you spend 
over the last 7 days doing vigorous physical activities?”  
__ __  Hours per week [VWHRS; Range: 0-112]     
   __ __ __ __Minutes per week [VWMIN; Range: 0-6720, 9998, 9999]   
   9998. Don't Know/Not Sure   
   9999. Refused   
   
READ:  Now think about activities which take moderate physical effort that you did in 
the last 7 days.  Moderate physical activities make you breathe somewhat harder than 
normal and may include carrying light loads, bicycling at a regular pace, or doubles 
IV 
 
tennis.  Do not include walking.  Again, think about only those physical activities that 
you did for at least 10 minutes at a time. 
 
3. During the last 7 days, on how many days did you do moderate physical activities? 
 ____ Days per week     [MDAY; Range: 0-7, 8, 9]       
  8. Don't Know/Not Sure   
  9. Refused  
   
[Interviewer clarification: Think only about those physical activities that you do for 
at least 10 minutes at a time]  
 
[Interviewer Note: If respondent answers zero, refuses or does not know, skip to 
Question 5] 
 
4. How much time did you usually spend doing moderate physical activities on one of 
those days? 
 __ __ Hours per day  [MDHRS; Range: 0-16]       
 __ __ __ Minutes per day     [MDMIN; Range: 0-960, 998, 999]    
998. Don't Know/Not Sure   
  999. Refused   
 
V 
 
[Interviewer clarification: Think only about those physical activities that you do for 
at least 10 minutes at a time.] 
 
[Interviewer probe: An average time for one of the days on which you do moderate 
activity is being sought. If the respondent can't answer because the pattern of time 
spent varies widely from day to day, or includes time spent in multiple jobs, ask: 
“What is the total amount of time you spent over the last 7 days doing moderate 
physical activities?” 
__ __ __  Hours per week   [MWHRS; Range: 0-112]   
__ __ __ __Minutes per week   [MWMIN; Range: 0-6720, 9998, 9999] 
9998. Don't Know/Not Sure   
   9999. Refused 
 
READ:  Now think about the time you spent walking in the last 7 days.  This 
includes at work and at home, walking to travel from place to place, and any 
other walking that you might do solely for recreation, sport, exercise, or 
leisure. 
 
5. During the last 7 days, on how many days did you walk for at least 10 minutes at a 
time? 
____ Days per week  [WDAY; Range: 0-7, 8, 9]      
8. Don't Know/Not Sure   
  9. Refused   
VI 
 
  
[Interviewer clarification: Think only about the walking that you do for at least 10 
minutes at a time.] 
 
[Interviewer Note: If respondent answers zero, refuses or does not know, skip to 
Question 7] 
 
 6. How much time did you usually spend walking on one of those days? 
 __ __  Hours per day   [WDHRS; Range: 0-16]        
 __ __ __  Minutes per day [WDMIN; Range: 0-960, 998, 999]      
998. Don't Know/Not Sure   
  999. Refused 
  
[Interviewer probe: An average time for one of the days on which you walk is being 
sought.  If the respondent can't answer because the pattern of time spent varies 
widely from day to day, ask: “What is the total amount of time you spent walking over 
the last 7 days?” 
 
__ __ __   Hours per week [WWHRS; Range: 0-112]     
__ __ __ __Minutes per week [WWMIN; Range: 0-6720, 9998, 9999]   
9998. Don't Know/Not Sure   
VII 
 
   9999. Refused 
 
READ: Now think about the time you spent sitting on week days during the 
last 7 days.  Include time spent at work, at home, while doing course work, and 
during leisure time.  This may include time spent sitting at a desk, visiting 
friends, reading or sitting or lying down to watch television. 
 
7. During the last 7 days, how much time did you usually spend sitting on a week day?
  
   __ __  Hours per weekday [SDHRS; 0-16]                         
    __ __ __ Minutes per weekday    [SDMIN; Range: 0-960, 998, 999]   
998. Don't Know/Not Sure   
 999. Refused 
                                                                                           
[Interviewer clarification: Include time spent lying down (awake) as well as 
sitting] 
 
[Interviewer probe: An average time per day spent sitting is being sought.  If the 
respondent can't answer because the pattern of time spent varies widely from day to 
day, ask: “What is the total amount of time you spent sitting last Wednesday?” 
__ __  Hours on Wednesday [SWHRS; Range 0-16]     
__ __ __   Minutes on Wednesday [SWMIN; Range: 0-960, 998, 999]    
998. Don't Know/Not Sure   
   999. Refused 
VIII 
 
Calcium intake study  
          Date: 
 
Name :     Age :   Hosp.No.: 
 
Height :    Weight :  BMI : 
 
 
Health problem :   Pann chewing : Smoking : 
 
Form 1 :  Meal Plan – 24 hrs recall  
Meal Time What and how much? 
Early morning 
 
 
 
 
 
 Coffee / tea / milk / kanchi 
Break fast 
 
 
 Idli       / dosa       / chappathi      / poori      / upma     / 
chappathi      / parotha      / semia       /  
 
IX 
 
 
 
 
Chutney – coconut /  groundnut /  tomato  /  onion 
Mid morning 
 
 
 
 
 
 Coffee / tea  /  milk  / kanchi  / juice  
 
Biscuits (ordinary / cream / salt / butter)   
cream bun / bun butter & jam   
bread butter and jam / cake (cream / ordinary) 
 
Samoza / puff (veg / egg / mutton / chicken) / vadai / 
bajji  
 
Lunch 
 
 
 
 
 
 Rice       /  sambar       /  rasam     /   karakulumbu 
Kurma   /  coconut kulumbu   
 
Muttan kulumbu / chicken kulumbu  / fish kulumbu 
Mutton /  chicken  / fish  / egg 
 
Carrot / beetroot / cauliflour / beans / lady’s finger / 
drumstick / brinjal / avaraikai  / cabbage / potato / 
X 
 
yam / colacacia  
 
Greens – seeri / aria / murunga / manathakali / avathi / 
ponaangani   
 
Tea time  
 
 
 
 
 
 
 Coffee / tea  /  milk  / kanchi  / juice  
 
Biscuits (ordinary / cream / salt / butter)   
cream bun / bun butter & jam   
bread butter and jam / cake (cream / ordinary) 
 
Samoza / puff (veg / egg / mutton / chicken) / vadai / 
bajji  
 
Dinner 
 
 
 
 
 
 Lunch pattern – 
 
Breakfast pattern -  
 
XI 
 
 
Bed time 
 
 
 
 
 
 
 Milk 
 
 
In between snacks & 
beverages 
 
 
 
 
 
 
 Fruits – apple / banana / grapes / orange / mosambi / 
sapota / mango / pomogra / pineapple / jackfruit /  
Type of oil used -    g.nut / coconut / gingelly / sunflower / dalda / butter / 
ghee  
   
 
XII 
 
      Annexure 2 
1.  ùTVo   : 
2. Gi   : 
3. ¡WôUm   : 
4. NUVm   : 
5. Lp®   : 
6. EVo Lp®  : 
7. ùRô¯p  : 
8. EVo ùRô¯p : 
9. UôR YÚUô]m : 
10. §ÚUQ ¨ûX : §ÚUQUô¡VYo / §ÚUQUôLôRYo / 
      ©¬kÕ YôrTYo / ®RûY 
©Wôdv-WHO GÛm× Ø±Ü Tô§l× Ï±jR BnÜ NôR]m 
 
1. YVÕ/©\kR úR§  : 
 
2. CûP (¡úXô ¡Wôm)  : 
 
3. EVWm (ùNu¥ ÁhPo) : 
 
4. Øu× GÛm× Ø±Ü HtThPRô : CpûX/Bm 
 
5. ùTtú\ôÚdÏ CÓl× GÛm× Ø±Ü HtThPRô : CpûX/Bm 
 
6. RtúTôÕ ×ûL©¥lÀWô : CpûX / Bm 
XIII 
 
 
 
7. ÏÞúLô Lôoh¥ LônÓv :   
 
8. ÚUhûPÓ BoRûWh¥Vô : CpûX / Bm 
 
 
9. ùNLuP¬ Jv¥úVô úTôúWôv : CpûX / Bm 
 
10. UÕTô]m êuß (A) ARtÏ A§Lm :  CpûX / Bm 
 
11. @ÀúUôWôp ùSL ©Gm¼ (g/cm2) 
 
T¬úNôRû] 
 
1. Gv.Lôp£Vm 
 
2. Gv.TôvúTh 
 
3. Gv.¡¬úV¥]u 
 
4. Gv.Bp×ªu 
T¥dLÜm : LPkR HÝ SôhL°p, ReLs GqY[Ü úSWm EPp EûZl× 
EiPôdÏm ùNVpLû[ ùNn¾oLs. EPp EûZl× ùNnVôRYWôL 
CÚkRôÛm, RVÜ ùNnÕ úLs®LÞdÏ T§p A°dLÜm. ¿eLs. 
Guù]u] ùNVpLû[ ùNn¡ÈoLs EeLs úYûX CPj§p Åh¥p, 
¨Xj§p, ©WVôQj§p Utßm EeLs Gg£V úSWj§p GkR 
XIV 
 
ùTôÝÕúTôdÏ, EPpT«t£ (ApXÕ) úYûXVôh¥p DÓTh¼oLs GuTûR 
úVô£dLÜm. 
 
T¥dLÜm : ¿eLs LPkR HÝ SôhL°p ùNnR L¥] EPp EûZl× 
ªÏkR LÓûUVô] ùNVpLs VôûYÙm ¨û]jÕd ùLôsÞeLs. 
LÓûUVô] ùNVpLs, EeLû[ NWôN¬dÏm A§LUôL êfÑ Cû\dL 
ûYdÏm, AûY YÛÕeÏYÕ, Ui ùYhÓYÕ, EPtT«t£ (ApXÕ) 
úYLUôL ûNd¡°eÏ. CkR EPp EûZl× Ïû\kRÕ 10 ¨ªPUôYÕ 
ùNn§ÚdL úYiÓm. 
 
1. CkR LPkR HÝ SôhL°p GjRû] SôhLs L¥] EPp úYûX 
 ùNn¾oLs? 
 __________ GjRû] SôhLs JÚ YôWj§p 
 8. ùR¬V®pûX / N¬VôL ùR¬V®pûX 
 9. ùNôpX UßlTÕ 
 
úSoØLm LôiúTôo ùR°ÜTÓjR úYi¥V : (Ïû\kRÕ 10 ¨ªPUôYÕ 
ùNnR EPp EûZl×s[ úYûX UhÓm ùNôpXÜm). 
 
úSoØLm LôiúTô¬u Ï±l× : T§p ùLôÓlTôo, Jußm T§p 
ùLôÓdL®pûX, T§p ùNôpX UßjRôúXô ApXÕ ùR¬V®pûX 
Gu\ôp úLs® êußdÏ (3) úTôLÜm. 
 
2. JÚ Sô°p, ¿eLs GqY[Ü úSWm L¥]UôL EPp EûZl× ªdL
 úYûXûV ùNnÅWoLs? 
 __________ JÚ Sô°p GjRû] U¦ úSWm 
 __________ JÚ Sô°p GjRû] ¨ªPm 
 998. ùR¬V®pûX / N¬VôL ùR¬V®pûX 
 999. T§p UßlTÕ. 
XV 
 
 
úSoØLm LôiúTôo ùR°ÜTÓjR úYi¥VÕ : 
 NWôN¬VôL JÚ Sôû[dÏ GqY[Ü úSWm L¥]UôL EPp EûZl× 
ªÏkR úYûXûV ùNnÅWoLs Guß úLhLÜm. T§p ùLôÓdL 
Ø¥V®pûX G²p, LôWQm AYo ùNXÜ ùNnÙm úSWm JqùYôÚ 
SôÞm úYßTÓm. BRXôp, ClT¥ úLhLÜm, GqY[Ü úSWm 
ùUôjRUôL LPkR HÝ SôhL°p, L¥]Uô] EPp EûZl× ªÏkR 
úYûXûV ùNn¾oL[ô? 
 
T¥dLÜm : 
 LPkR HÝ SôhL°p, ¿eLs ªRUô] (KW[Ü) EPp EûZl×s[ 
úYûXLs Guù]u] ùNn¾oLs Guß SôTLTÓjÕeLs. ªRUô] 
(KW[Ü) EPp EûZl× Es[ úYûXLs ùNnÙmúTôÕ KW[Ü êfÑ 
Cû\dÏm. Ïû\Yô] CûPÙs[ AûUûV ÕdÏYÕ, ûNd¡s ªRUô] 
úYLj§p KhÓYÕ (ApXÕ) CWhûPVôo ùPu²v BÓYÕm B¡VûY 
C§p APeÏm. C§p SPlTÕ Es[PeLôÕ. Ï±lTôL, CkR Aû]jÕ 
EPp EûZl× JqùYôußm Ïû\kRÕ 10 ¨ªPUôYÕ ùNn§ÚdL 
úYiÓm. 
 
3. LPkR HÝ SôhL°p, ¿eLs GjRû] SôhLs ªRUô] EPp 
EûZl×s[ úYûXLû[ ùNn¾oLs? 
 __________ YôWj§p GjRû] SôhLs 
 8. ùR¬V®pûX / N¬VôL ùR¬V®pûX 
 9. T§p ùLôÓdL UßlTÕ. 
 
4. ¿eLs GjRû] U¦úSWm ªRUô] EPp EûZl×s[ 
úYûXLû[ JÚ Sô°p ùNnÅoLs? 
 __________ JÚ Sô°p GjRû] U¦ úSWm 
 __________ JÚ Sô°p GjRû] ¨ªPeLs 
 998. ùR¬V®pûX / N¬VôL ùR¬V®pûX 
XVI 
 
 999. T§p ùLôÓdL UßlTÕ. 
 
úSoØLm LôiúTôo ùR°ÜTÓjR úYi¥VÕ : Ïû\kRÕ 10 
¨ªPUôYÕ. ùNnR EPp EûZl×s[ úYûXûV UhÓm ùNôpXÜm. 
 
úSoØLm LôiúTôo ùR°ÜTÓjR úYi¥VÕ : Ïû\kRÕ 10 ¨ªPUôYÕ 
ùNnR EPp EûZl×s[ úYûX UhÓm ùNôpXÜm. 
 
úSoØLm LôiúTô¬u Ï±l× : T§p ùLôÓlúTôo Jußm T§p 
ùLôÓdL®pûX, T§p ùNôpX UßjRôúXô (A) ùR¬V®pûX Gu\ôp 
úLs® (5) ùNpXÜm. 
 
úSoØLm LôiúTô¬u úLs®Ls 
 NWôN¬VôL GqY[Ü U¦ úSWm JÚ Sôû[dÏ ¿eLs ªRUô] 
EPp EûZl×s[ úYûXLû[ ùNnÅoLs. N¬Vô] T§p ùLôÓdL 
Ø¥V®pûX Gu\ôp LôWQm AYo JqùYôÚ úYûXdÏ ùNXÜ 
ùNnÙm úSWm. JqùYôÚ SôÞm úYßTÓm Utßm TtTX úYûXLs  
ùNnYÕm APeÏm. BRXôp, LPkR HÝ SôhL°p ùUôjRUôL GqY[Ü 
úSWm ªRUô] EPp EûZl×s[ úYûXLs ùNn¾oLs G] úLhLÜm? 
 __________ GjRû] U¦ úSWm JÚ YôWj§p 
 __________ GjRû] ¨ªPeLs JÚ YôWj§p 
 9998. ùR¬V®pûX / N¬VôL ùR¬V®pûX 
  9999. T§p ùLôÓdL UßlTÕ. 
 
T¥dLÜm : 
 ¿eLs LPkR HÝ SôhL°p, GjRû] úSWm SPlTRtÏ ùNXÜ 
ùNn¾oLs. C§p úYûX CPj§p SPlTÕ, Utßm Åh¥p, ©WVôQj§u 
úTôÕ, ùTôÝÕ úTôdLôL SPlTÕ, ®û[Vôh¥u úTôÕ EPp T«t£«u 
úTôÕ (A) KnÜ úSWm ¡ûPdÏm úTôÕ SPlTÕm APeÏm. 
 
XVII 
 
5. LPkR HÝ SôhL°p, GjRû] SôhLs TjÕ ¨ªPUôYÕ SPk¾oLs? 
 __________ GjRû] SôhLs / JÚ YôWj§p 
 8. ùR¬V®pûX / N¬VôL ùR¬V®pûX. 
 9. T§p ùLôÓdL UßlTÕ. 
 
úSoØLm LôiúTôo ùR°ÜTÓjR úYi¥VÕ : Ïû\kRÕ 10 ¨ªPUôYÕ 
ùNnR EPp EûZl×s[ úYûX UhÓm ùNôpXÜm. 
 
úSoØLm LôiúTô¬u Ï±l× : T§p ùLôÓlúTôo Jußm T§p 
ùLôÓdL®pûX, T§p ùNôpX UßjRôúXô (A) ùR¬V®pûX Gu\ôp 
úLs® (7) ùNpXÜm. 
 
6. JÚ Sôû[dÏ GqY[Ü úSWm SPlTRtL ùNXÜ ùNnÅoLs? 
 __________ JÚ Sôû[dÏ GjRû] úSWm 
 __________ JÚ Sôû[dÏ GqY[Ü ¨ªPm 
 998. ùR¬V®pûX / N¬VôL ùR¬V®pûX 
  999. T§p ùLôÓdL UßlTÕ. 
 
(úSoØLm LôiúTôo úUÛm úLhL úYi¥VÕ) 
 
 NWôN¬VôL, JÚ Sôû[dÏ GqY[Ü úSWm SPlÀoLs GuTûR 
ùR¬V ®Úm×¡ú\u. JÚ úYû[, N¬Vô] T§p ¡ûPdL®pûX G²p, 
ARtÏ LôWQm JqùYôÚ SôÞm SPlTRtÏ ùNX®Óm úSWm 
úYßTÓm. BRXôp ClT¥ úLhLÜm, LPkR HÝ SôhL°p ùUôjRUôL 
GqY[Ü úSWm SPd¡ÈoLs? 
 __________ JÚ YôWj§tÏ GjRû] úSWm. 
 __________ JÚ YôWj§tÏ GjRû] ¨ªPm. 
 9998. ùR¬V®pûX / N¬VôL ùR¬V®pûX  
XVIII 
 
  9999. T§p ùLôÓdL UßlTÕ. 
 
T¥dLÜm : 
 LPkR HÝ SôhL°p, ¿eLs GqY[Ü úSWm TLp úSWeL°p 
EhLôok§Úk¾oLs. C§p úYûX CPeL°p EhLôokRÕ, Åh¥p,    
Utßm ùTôÝÕúTôdÏm úTôÕ EhLôok§ÚdÏm úSWØm APeÏm. C§p 
úUû_«p EhLôok§ÚRp, SiToLû[ Nk§jRp, T¥jRp ApXÕ 
EhLôok§ÚjRp, TÓjÕd ùLôiÓ ùRôûXdLôh£ TôojRôÛm APeÏm. 
 
7. LPkR GÝ SôhL°p, GjRû] úSWm JÚ YôWj§p TLp úSWeL°p 
EhLôok§ÚlÀoLs? 
 __________ JÚYôWj§p GjRû] úSWm 
 __________ JÚYôWj§p GjRû] ¨ªPm 
 ùR¬V®pûX/N¬VôL ùR¬V®pûX 
 T§p ùLôÓdL UßjRp 
 
(úSoØLm LôiúTo ùR°ÜTÓjR úYi¥VÕ) 
TÓj§ÚjRp Utßm EhLôÚRp úSWØm APeÏm. 
 
(úSoØLm LôiúTôo úUÛm úLhL úYi¥VÕ) 
NWôN¬ JÚ Sô°p GqY[Ü úSWm. EhLôok§ÚlÀoLs. T§p ùLôÓlúTôo 
úLs® RW Ø¥V®pûX G²p, LôWQm AYo úSWm ùNXÜ ùNnÙm 
A[Ü JqùYôÚ SôÞm úYßTÓm. BRXôp ClT¥ úLhLÜm, LPkR 
×Ru¡ZûU, ¿eLs ùUôjRUôL GqY[Ü úSWm EhLôok§Úk¾oLs. 
 __________ ×Ru Auß ùNXÜ ùNnR úSWm 
 __________ ×Ru Auß ùNXÜ ùNnR ¨ªPeLs 
 998. ùR¬V®pûX/N¬VôL ùR¬V®pûX 
  999. T§p ùLôÓdL Ußl× 
XIX 
 
Lôp£Vm Esú[ÓjRp Tt±V BnÜ 
          úR§ : 
ùTVo :     YVÕ :  BnÜ Gi. 
EVWm :     CûP :  ©.Gm.I : 
EPp ©WfNû] :    TôuùUsÞYÕ : 
×ûL ©¥jRp 
 
`ôm 1 : EQÜ §hPm  - 24 U¦ úSWm Nôl©hP EQûY 
OôTLTÓjRp. 
 
EQÜ 
 
úSWm Gu] Utßm GqY[Ü? 
A§LôûX  Lô©/¼/Tôp/Lg£ 
 
LôûX EQÜ 
(¥Tu) 
 Ch−/úRôûN/NmUôj§/é¬/ El×Uô/ 
NlTôj§/TúWôhPô/úNªVô 
Nh¥²-úReLôn/úYoLPûX/ 
RdLô°/ùYeLôVm 
 
SÓ LôûX  Lô©/¼/Tôp/Lg£/T¥Nôß 
©vùLh (NôRôWQUô]/¡¬m/El×/ 
ùYsû[) ¡ÃmTu/Tu ThPo Utßm 
_ôm ©úWôÓ ThPo Utßm _ôm/úLd 
(¡Ãm/NôRôWQm/ NúUôN/ 
TlÑ(ùYw/ØhûP/UhPu/£dLu) 
XX 
 
YûP/Tw£ 
 
Uj§V EQÜ  NôRm/NmTôo/WNm/LôûWdÏ[m×/ 
ÏÚUô/úReLôn Ï[m× 
 
ThPu Ï[m×/£dLu Ï[m×/ Áu 
Ï[m× 
 
UhPu/£dLu/Áu/ØhûP 
 
úLWÓ/©hÏÚ/Lô°©[Yo/©uv/ 
ùYiPdLôn/ØÚeûLLôn/ 
Lj§¬dLôn/AYûWdLôn/úLôv/ 
EÚû[d¡ZeÏ/úNûUd¡ZeÏ 
 
TfûNdLônL±-£ß¡ûW/AWd¡ûW/ 
ØÚeL¡ûW/U]RdLô°/AYj§¡ûW/ 
ùTôu]ôeÏ² 
 
UôûX úSWm   
 
 
CWÜ EQÜ   
 
 
TÓdûL úSWm  Tôp 
 
 
SÓ®p 
EhùLôsÞRp 
(£]dv/ùYùWw) 
 TZeLs-Bl©p/YôûZlTZm/§WôhûN/ 
BúWgÑ/ØNôm©/NlúTôhPô/UômTZm/ 
UôÕ[m/Au]ôf£/TXôTZm 
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Annexure 4 
Information sheet 
Name of the principle investigator: Dr. Reshma Raju 
Name of the organization: Department of community health, Christian Medical College, 
Vellore 
Title: A study to find out the percentage of ambulatory elderly men with osteoporosis(weak 
bones with increased fracture risk) and its causes in Kaniyambadi block 
we are doing a study to find out the percentage of men with osteoporosis and its causes in 
kaniyambadi block. We are inviting you to participate in the study. Please review this form 
carefully and ask any questions about the study before you agree to join. You may also ask 
questions at any time after joining the study 
Purpose:  
Elderly population is at increased risk for osteoporosis and subsequent fractures. Fractures in 
elderly have a huge economic burden on the family and the community. Most of the data 
available regarding osteoporosis is from studies done in women. Since the data from men are 
lacking this study purposes to find the percentage of men with osteoporosis and its causes in 
Kaniyambadi block.  
.  
Procedure: You are invited to participate in the study. A questionnaire will be administered 
to you. You will be asked to go to CMC Vellore for a Dexa scan(similar to X ray) and blood 
tests. Travel expenses will be taken care of as part of the study. 
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Side effects: No side effects are contemplated because Dexa scan uses very low dose of X 
ray which is one tenth the dose used in a chest X ray.  
Risks and discomfort: There will not be any or discomfort to you as the procedure(Dexa 
scan) is non-invasive. Blood sample will be taken in CMC to check for your Serum Calcium, 
phosphate, albumin and creatinine values. 
Benefits: Your participation is likely to help us find answers about osteoporosis in men. This 
information will help us to use strategies to prevent the development of osteoporosis in men 
and thus reduce the incidence of fractures among elderly men. 
Expenses: All investigations will be done free of cost for the patient. No cash incentives will 
be given for taking part in the study. Travel expense (to CMC and back) will be taken care of 
by the study. 
Confidentiality: The information that we collect from this research project will be kept 
confidential. Information about you that will be collected from the study will be stored in a 
file and will be kept locked with access only to the primary investigator.  
Right to refuse or withdraw: You do not have to join in this research if you do not wish to 
do so. You may stop participation in the research at any time without losing any of your 
rights as a patient here. Your treatment at this center will not be affected in any way. 
If new information becomes available: Sometimes, after a research study has started, the 
researchers learn new things about osteoporosis. If this happens, we will tell you about the 
new information. Then you can decide whether you will continue participating. 
Whom to contact: If you have any questions you may ask them now or later. If you wish to 
ask questions later, you may contact any of the following: 
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     Annexure 5 
RLYp Rôs 
 
RûXûU BnYô[¬u ùTVo : PôdPo.úWxUô Wô_÷ 
 
¨oYôLj§u ùTVo :  NêL ÑLôRôWjÕû\, ¡ÚjÕY UÚjÕYd Lpí¬, 
     úYío. 
RûXl× : 
 L¦VmTô¥ YhPôWj§p, Bv¥úVô úTôúWô£vNôp Tô§dLlThP 
BiL°u NRÅRm Utßm ARu LôWQeLs LiP±YRtLôL CkR 
BnûY SPjÕ¡ú\ôm. SôeLs EeLû[ CkR Bn®p TeúLtTRtÏ 
AûZd¡ú\ôm. 
 CkR Bn®p úNW, NmU§dÏm Øu]RôL CkR T¥Yj§û] 
LY]UôL T¥jÕ AÕ NmUkRUôL HúRàm úLs®Ls CÚkRôp 
úLhLXôm. 
 Bn®p úNojR ©\Ïm, EeLÞdÏ HúRàm úLs®Ls CÚkRôp 
GkúSWØm RôWô[UôL úLhLXôm. 
XXV 
 
 
úSôdLm : 
 Bv¥úVôúTôWô³v-dÏm, GÛm× Ø±ÜdÏm ùT¬VYoLs A§L 
Tô§l×dÏ Es[ô¡\ôoLs. 
 
 NØRôVj§Ûm Utßm ÏÓmTj§Ûm CkR Uô§¬Vô] Ø±ÜLs 
ùT¬VYoLs ÁÕ ùTôÚjR TQf ÑûUûV ûYd¡u\]. 
 
 Bv¥úVôúTôWô³v NmUkRUô] TX RLYpLs ùTiL°Pm GÕ 
SPjRlThP Bn®u êXm ¡ûPdLlùTt\Õ. CkR RLYp BiLs 
Tt± CpXôRRôp. CkR BnÜ SPjRlTÓ¡\Õ. 
 
ùNnØû\ : 
 ¿eLs CkR BnÜdÏ AûZdLlTÓ¡ÈoLs. JÚ úLs®jRôs 
ReL°Pm A°dLlTÓm. ¿eLs, £.Gm.£. úYí¬p, ùPdNô vúLu 
ùNnV AûZdLlTÓYôoLs. (X-Ray Uô§¬Vô]) Utßm CWjR T¬úNôRû]. 
Bn®u JÚ TÏ§VôL úTôdÏYWjÕ ùNXÜLs RWlTÓm. 
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TdL ®û[ÜLs : 
 GkR TdL ®û[ÜLÞm ¡ûPVôÕ. Hu Gu\ôp ùPdNô vúLu 
GuTÕ ªLÜm Ïû\kR X-Ray úPôu AûYúV TVuTÓjÕ¡\Õ. 
ARôYÕ Uôo× X-Ray-®p, Tj§p ©\ TeÏ TVuTÓjRlTÓ¡\Õ. 
BTjÕ Utßm AùN[L¬Vm : 
 CkR ùNVpØû\Vôp GkR JÚ BTjÕm, AùN[L¬VØm 
¡ûPVôÕ. Hù]²p CkR ùNn Øû\Vôp GkR JÚ LÚ®Ùm 
EPÛdÏs ùNÛjRlTPUôhPôÕ. 
 
 Lôp£Vm, TôvúTh, Bp×ªu Utßm ¡¬VôP²u U§lÀÓLû[ 
A±V £.Gm.£.«p CWjRm GÓdLlTÓm. 
 
TVuLs : 
 BiL°u Bv¥úVôúTôWô³v NmUkRlThP ®ûPLû[ LiÓ 
A±YRtÏ ReL°u TeL°l× ER®LWUôL CÚdÏm. 
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 BiL°p Bv¥úVôúTôWô³v Øuú]t\m AûPVôUp 
RÓlTRtLô] Ùd§Lû[ YÏdL CkR RLYp ER®VôL CÚdÏm. úUÛm 
ùT¬VYoL°p GÛm× NmUkRUô] Ø±ÜLs Ïû\dL ERÜm. 
 
ùNXÜLs :  
 GpXô T¬úNôRû]LÞm CXYNUôL ùNnÕ RWlTÓm. CkR Bn®p 
TeúLtTRtÏ GkR JÚ NkUô]Øm RWlTPUôhôÕ. úTôdÏYWjÕ 
ùNXÜLû[  BnúY ùTôßl× HtÏm. 
 
CWL£V RuûU : 
 CkR Bn®u êXm úNL¬dLlTÓm Aû]jÕ RLYpLÞm 
CW¡VUôL TôÕLôdLlTÓm. 
 
 úNL¬dLlThP EeL°u RLYpLs Tj§WUôL JÚ úLôl©p éh¥ 
ûYdLlTÓm. AûR RûXûU BnYô[o GÓdL UhÓúU AàU§ EiÓ. 
 
UßdÏm E¬ûU (A) ©uYôeÏYÕ : 
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 EeLÞdÏ ®ÚlTm CpûX Gu\ôp CkR Bn®p úNW 
úYiPôm. 
 
×§V ùNn§Ls CÚdÏUô]ôp : 
 CkR BWônf£ûV úUtùLôiP BWônf£Vô[Wôp CkR úSôn  
(Bv¥úVô úTôWô³v) Tt±V ×§V ùNn§ (A) RLYp ¡ûPjRôp 
BWônf£Vô[o AûRlTt± EeL°Pm ùNôpYôoLs. CRtÏ ©u 
¿eL[ EeLs ®ÚlTm CÚkRôp C§p LXkÕ ùLôs[Xôm. 
 
ùRôPo×ùLôs[ úYi¥V STo :  
 EeLÞdÏ HúRàm úLs® CÚkRôp, ¿eLs ClúTôÕ (A) 
GlúTôÕm CkR BWônf£Vô[¬Pm úLhLXôm.  
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Annexure 6 
  
Informed Consent form to participate in a research study  
 
Study Title: Prevalence and risk factors for osteoporosis in ambulatory elderly men in a rural 
area of South India: a cross sectional study 
Study Number: ____________Subject’s  Initials:___________  
Subject’sName: _________________________________________ 
Date of Birth / Age: ___________________________ 
 
(i)  I confirm that I have read and understood the information sheet dated ____________ 
for the above study and have had the opportunity to ask questions. [  ] 
(ii)  I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or legal 
rights being affected. [  ] 
(iii)  I understand that the Sponsor of the study, others working on the Sponsor’s behalf, 
the Ethics Committee and the regulatory authorities will not need my permission to 
look at my health records both in respect of the current study and any further research 
that may be conducted in relation to it, even if I withdraw from the trial. I agree to 
this access. However, I understand that my identity will not be revealed in any 
information released to third parties or published. [  ] 
XXX 
 
 
(iv)  I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s). [  ] 
(v)  I agree to take part in the above study. [  ] 
Signature (or Thumb impression) of the Subject/Legally Acceptable  
Date: _____/_____/______ 
Signatory’s Name: _________________________________         Signature:  
Or 
 
Representative: _________________ 
Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
Signature of the Investigator: ________________________ 
Date: _____/_____/______ 
Study Investigator’s Name: ________________________ 
Signature or thumb impression of the Witness: ___________________________ 
Date: _____/_____/_______ Name & Address of the Witness: 
_____________________________ 
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Annexure 7 
CkR Bn®p TeÏ ùTßúYôÚdLô] Jl×Rp T¥Ym 
RûXl× : 
 L¦VmTô¥ YhPôWj§p, Bv¥úVôúTôWô³vNôp Tô§dLlThP 
BiL°u NRÅRm Utßm ARu LôWQeLû[ LiP±YRtLôL CkR 
BnûY SPjÕ¡ú\ôm. SôeLs EeLû[ CkR Bn®p TeúLtTRtÏ 
AûZd¡ú\ôm. 
T¥Y Gi :  
Jl×RpLôW¬u ùTVo : 
©\kR úR§ / YVÕ : 
1.  Sôu RLYp Rô°p Es[ RLYpLû[ T¥jÕ Eß§VôL ùR¬kÕ 
ùLôiúPu, Utßm G]dÏ A§p Es[ CkR NkúRLeLû[ úLhÓ 
ùR¬kÕ ùLôs[ NkRolTØm ¡ûPjRÕ. 
2. GuàûPV TeL°l× CkR Bn®p ÑVUô]Õ, E]dÏm GlúTôÕ 
CkR Bn®p CÚkÕ ®XL úYiÓúUô AlúTôÕ GkR JÚ LôWQØm 
Cu±, UÚjÕ YN§ Utßm GuàûPV NhP E¬ûU GÕÜm 
Tô§dLlTPôÕ GuTûR ×¬kÕ ùLôiúPu. 
3. CkR BnûY SPjÕTYWôúXô ApXÕ SPjÕm ¨ßY]j§]ôúXô 
GuàûPV BúWôd¡V T¥YjûR GuàûPV AàU§«u± CkR 
An®tLôL TôodLXôm, AYoLÞûPV Bn®p CÚkÕ Sôu Tô§«p 
ùY°úV±]ôÛm AûRlTt± ùNn§LÞdÏ Gu²Pm T¡okÕ 
ùLôs[Xôm. Sôu CûR JjÕdùLôs¡ú\u. GuàûPV AûPVôu 
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GkR JÚ êu\ôm ST¬PØm T¡okÕ ùLôs[lTPôÕ GuTûR ×¬kÕ 
ùLôs¡ú\u. 
4. CkR A±®Vp BWônf£dLôL úLhLlTÓm Aû]jÕ 
úLs®Lû[Ùm, RLYpLû[Ùm ¨WôL¬dLUôhúPu. 
5. Sôu CkR Bn®p TeùLÓdL ®Úm×¡ú\u.  
ûLùVÝjÕ (ApXÕ) CPÕ ùTÚ®Wp Øj§ûW) 
Bn®u êXUôL NhPléoYUôL Jl×R 
úR§ :       ûLùVÝjÕ 
BnYô[¬u ùTVo 
(ApXÕ) 
 
Ñt\ôRôW¬u ûLùVôlTm   úR§  : 
BnYô[¬u ùTVo : 
BnYô[¬u ûLùVÝjÕ :    úR§ 
Nôh£ ûLùVÝjÕ     úR§ :   
 Nôh£«u ùTVo Utßm ØLY¬ : 
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